index,title,abstract,Master Ref#,PubMed ID,Journal,Primary Author,Publication Year,Volume / Issue,Pages,Priority Journal,PubMed ID:,Full Reference:,"Study Outcome ($/QALY, $/DALY, Both):",Study Country:,Disease Classification:,Intervention Type(s):,Intervention Phrase vs. Comparator Phrase:,Target Characteristics:,Max Target Age:,Min Target Age:,Target Genders:,Review:,Time Horizon:,Discounting Rate (Costs):,Discounting Rate (QALYs):,Incremental Cost-Effectiveness Ratio (Original currency and year):,Currency Country:,Currency Year:,Incremental Cost-Effectiveness Ratio (Converted to current $USD):
26101,Choosing cost-effective interventions in psychiatry: results from the CHOICE programme of the World Health Organization,"There is increasing recognition at both the international and national level of the disease burden attributed to psychiatric disorders, yet little is known about how much of this burden is or could be averted by current or scaled-up implementation of effective interventions. In addition, little is known about the costs and cost-effectiveness of such interventions in most regions of the world, even though such information is of direct relevance to increased investment and service development. This research report provides an overview of the mental health component of the World Health Organization's CHOICE project, the aim of which is to generate cost-effectiveness evidence for a large number of interventions for leading contributors to disease burden in a range of geographical and epidemiological settings around the world. To date, expected costs (expressed in international dollars) and effects (measured in terms of disability adjusted life years, DALYs) of key pharmacological and psychosocial interventions have been modelled for schizophrenia, bipolar disorder, depression and panic disorder. The results of this analysis indicate that the most efficient interventions for common mental disorders (depression and panic disorder) can be considered very cost-effective (each DALY averted costs less than one year of average per capita income), while community-based interventions for more severe mental disorders using older antipsychotic and mood stabilising drugs meet the criterion for being cost-effective (each DALY averted costs less than three times the average annual income). These findings provide relevant new information to health policy makers regarding the relative value of investing in psychiatric care, and in so doing may help to remove one of many remaining barriers to a more appropriate public health response to the burden of these conditions.",2005-99-01544,16633504,World Psychiatry,Dan Chisholm,2005,4 / 1,37-44,No,16633504,"Dan Chisholm; Choosing cost-effective interventions in psychiatry: results from the CHOICE programme of the World Health Organization, World Psychiatry, 2005-Feb; 4(1):1723-8617; 37-44",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Maintenance psychosocial treatment plus newer antidepressant drug (Selective serotonin reuptake inhibitor) vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,2487,United States,2003,3498.17
26102,Choosing cost-effective interventions in psychiatry: results from the CHOICE programme of the World Health Organization,"There is increasing recognition at both the international and national level of the disease burden attributed to psychiatric disorders, yet little is known about how much of this burden is or could be averted by current or scaled-up implementation of effective interventions. In addition, little is known about the costs and cost-effectiveness of such interventions in most regions of the world, even though such information is of direct relevance to increased investment and service development. This research report provides an overview of the mental health component of the World Health Organization's CHOICE project, the aim of which is to generate cost-effectiveness evidence for a large number of interventions for leading contributors to disease burden in a range of geographical and epidemiological settings around the world. To date, expected costs (expressed in international dollars) and effects (measured in terms of disability adjusted life years, DALYs) of key pharmacological and psychosocial interventions have been modelled for schizophrenia, bipolar disorder, depression and panic disorder. The results of this analysis indicate that the most efficient interventions for common mental disorders (depression and panic disorder) can be considered very cost-effective (each DALY averted costs less than one year of average per capita income), while community-based interventions for more severe mental disorders using older antipsychotic and mood stabilising drugs meet the criterion for being cost-effective (each DALY averted costs less than three times the average annual income). These findings provide relevant new information to health policy makers regarding the relative value of investing in psychiatric care, and in so doing may help to remove one of many remaining barriers to a more appropriate public health response to the burden of these conditions.",2005-99-01544,16633504,World Psychiatry,Dan Chisholm,2005,4 / 1,37-44,No,16633504,"Dan Chisholm; Choosing cost-effective interventions in psychiatry: results from the CHOICE programme of the World Health Organization, World Psychiatry, 2005-Feb; 4(1):1723-8617; 37-44",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Benzodiazepine vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,1332,United States,2003,1873.57
26103,Choosing cost-effective interventions in psychiatry: results from the CHOICE programme of the World Health Organization,"There is increasing recognition at both the international and national level of the disease burden attributed to psychiatric disorders, yet little is known about how much of this burden is or could be averted by current or scaled-up implementation of effective interventions. In addition, little is known about the costs and cost-effectiveness of such interventions in most regions of the world, even though such information is of direct relevance to increased investment and service development. This research report provides an overview of the mental health component of the World Health Organization's CHOICE project, the aim of which is to generate cost-effectiveness evidence for a large number of interventions for leading contributors to disease burden in a range of geographical and epidemiological settings around the world. To date, expected costs (expressed in international dollars) and effects (measured in terms of disability adjusted life years, DALYs) of key pharmacological and psychosocial interventions have been modelled for schizophrenia, bipolar disorder, depression and panic disorder. The results of this analysis indicate that the most efficient interventions for common mental disorders (depression and panic disorder) can be considered very cost-effective (each DALY averted costs less than one year of average per capita income), while community-based interventions for more severe mental disorders using older antipsychotic and mood stabilising drugs meet the criterion for being cost-effective (each DALY averted costs less than three times the average annual income). These findings provide relevant new information to health policy makers regarding the relative value of investing in psychiatric care, and in so doing may help to remove one of many remaining barriers to a more appropriate public health response to the burden of these conditions.",2005-99-01544,16633504,World Psychiatry,Dan Chisholm,2005,4 / 1,37-44,No,16633504,"Dan Chisholm; Choosing cost-effective interventions in psychiatry: results from the CHOICE programme of the World Health Organization, World Psychiatry, 2005-Feb; 4(1):1723-8617; 37-44",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Tricyclic antidepressants vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,1057,United States,2003,1486.76
26104,Choosing cost-effective interventions in psychiatry: results from the CHOICE programme of the World Health Organization,"There is increasing recognition at both the international and national level of the disease burden attributed to psychiatric disorders, yet little is known about how much of this burden is or could be averted by current or scaled-up implementation of effective interventions. In addition, little is known about the costs and cost-effectiveness of such interventions in most regions of the world, even though such information is of direct relevance to increased investment and service development. This research report provides an overview of the mental health component of the World Health Organization's CHOICE project, the aim of which is to generate cost-effectiveness evidence for a large number of interventions for leading contributors to disease burden in a range of geographical and epidemiological settings around the world. To date, expected costs (expressed in international dollars) and effects (measured in terms of disability adjusted life years, DALYs) of key pharmacological and psychosocial interventions have been modelled for schizophrenia, bipolar disorder, depression and panic disorder. The results of this analysis indicate that the most efficient interventions for common mental disorders (depression and panic disorder) can be considered very cost-effective (each DALY averted costs less than one year of average per capita income), while community-based interventions for more severe mental disorders using older antipsychotic and mood stabilising drugs meet the criterion for being cost-effective (each DALY averted costs less than three times the average annual income). These findings provide relevant new information to health policy makers regarding the relative value of investing in psychiatric care, and in so doing may help to remove one of many remaining barriers to a more appropriate public health response to the burden of these conditions.",2005-99-01544,16633504,World Psychiatry,Dan Chisholm,2005,4 / 1,37-44,No,16633504,"Dan Chisholm; Choosing cost-effective interventions in psychiatry: results from the CHOICE programme of the World Health Organization, World Psychiatry, 2005-Feb; 4(1):1723-8617; 37-44",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Newer antidepressant drug (Selective serotonin reuptake inhibitor; generic) vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,1219,United States,2003,1714.62
26105,Choosing cost-effective interventions in psychiatry: results from the CHOICE programme of the World Health Organization,"There is increasing recognition at both the international and national level of the disease burden attributed to psychiatric disorders, yet little is known about how much of this burden is or could be averted by current or scaled-up implementation of effective interventions. In addition, little is known about the costs and cost-effectiveness of such interventions in most regions of the world, even though such information is of direct relevance to increased investment and service development. This research report provides an overview of the mental health component of the World Health Organization's CHOICE project, the aim of which is to generate cost-effectiveness evidence for a large number of interventions for leading contributors to disease burden in a range of geographical and epidemiological settings around the world. To date, expected costs (expressed in international dollars) and effects (measured in terms of disability adjusted life years, DALYs) of key pharmacological and psychosocial interventions have been modelled for schizophrenia, bipolar disorder, depression and panic disorder. The results of this analysis indicate that the most efficient interventions for common mental disorders (depression and panic disorder) can be considered very cost-effective (each DALY averted costs less than one year of average per capita income), while community-based interventions for more severe mental disorders using older antipsychotic and mood stabilising drugs meet the criterion for being cost-effective (each DALY averted costs less than three times the average annual income). These findings provide relevant new information to health policy makers regarding the relative value of investing in psychiatric care, and in so doing may help to remove one of many remaining barriers to a more appropriate public health response to the burden of these conditions.",2005-99-01544,16633504,World Psychiatry,Dan Chisholm,2005,4 / 1,37-44,No,16633504,"Dan Chisholm; Choosing cost-effective interventions in psychiatry: results from the CHOICE programme of the World Health Organization, World Psychiatry, 2005-Feb; 4(1):1723-8617; 37-44",DALY,Not Stated,Not Stated,Health Education or Behavior,Cognitive behavioral therapy vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,1271,United States,2003,1787.77
26106,Choosing cost-effective interventions in psychiatry: results from the CHOICE programme of the World Health Organization,"There is increasing recognition at both the international and national level of the disease burden attributed to psychiatric disorders, yet little is known about how much of this burden is or could be averted by current or scaled-up implementation of effective interventions. In addition, little is known about the costs and cost-effectiveness of such interventions in most regions of the world, even though such information is of direct relevance to increased investment and service development. This research report provides an overview of the mental health component of the World Health Organization's CHOICE project, the aim of which is to generate cost-effectiveness evidence for a large number of interventions for leading contributors to disease burden in a range of geographical and epidemiological settings around the world. To date, expected costs (expressed in international dollars) and effects (measured in terms of disability adjusted life years, DALYs) of key pharmacological and psychosocial interventions have been modelled for schizophrenia, bipolar disorder, depression and panic disorder. The results of this analysis indicate that the most efficient interventions for common mental disorders (depression and panic disorder) can be considered very cost-effective (each DALY averted costs less than one year of average per capita income), while community-based interventions for more severe mental disorders using older antipsychotic and mood stabilising drugs meet the criterion for being cost-effective (each DALY averted costs less than three times the average annual income). These findings provide relevant new information to health policy makers regarding the relative value of investing in psychiatric care, and in so doing may help to remove one of many remaining barriers to a more appropriate public health response to the burden of these conditions.",2005-99-01544,16633504,World Psychiatry,Dan Chisholm,2005,4 / 1,37-44,No,16633504,"Dan Chisholm; Choosing cost-effective interventions in psychiatry: results from the CHOICE programme of the World Health Organization, World Psychiatry, 2005-Feb; 4(1):1723-8617; 37-44",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Older antidepressant drug (tricyclic antidepressants) plus psychosocial treatment vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,1584,United States,2003,2228.03
26107,Choosing cost-effective interventions in psychiatry: results from the CHOICE programme of the World Health Organization,"There is increasing recognition at both the international and national level of the disease burden attributed to psychiatric disorders, yet little is known about how much of this burden is or could be averted by current or scaled-up implementation of effective interventions. In addition, little is known about the costs and cost-effectiveness of such interventions in most regions of the world, even though such information is of direct relevance to increased investment and service development. This research report provides an overview of the mental health component of the World Health Organization's CHOICE project, the aim of which is to generate cost-effectiveness evidence for a large number of interventions for leading contributors to disease burden in a range of geographical and epidemiological settings around the world. To date, expected costs (expressed in international dollars) and effects (measured in terms of disability adjusted life years, DALYs) of key pharmacological and psychosocial interventions have been modelled for schizophrenia, bipolar disorder, depression and panic disorder. The results of this analysis indicate that the most efficient interventions for common mental disorders (depression and panic disorder) can be considered very cost-effective (each DALY averted costs less than one year of average per capita income), while community-based interventions for more severe mental disorders using older antipsychotic and mood stabilising drugs meet the criterion for being cost-effective (each DALY averted costs less than three times the average annual income). These findings provide relevant new information to health policy makers regarding the relative value of investing in psychiatric care, and in so doing may help to remove one of many remaining barriers to a more appropriate public health response to the burden of these conditions.",2005-99-01544,16633504,World Psychiatry,Dan Chisholm,2005,4 / 1,37-44,No,16633504,"Dan Chisholm; Choosing cost-effective interventions in psychiatry: results from the CHOICE programme of the World Health Organization, World Psychiatry, 2005-Feb; 4(1):1723-8617; 37-44",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Newer antidepressant drug (Selective serotonin reuptake inhibitor; generic) plus psychosocial treatment vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,1720,United States,2003,2419.32
26108,"Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence","BACKGROUND: The HIV epidemic has caused a dramatic increase in tuberculosis (TB) in East and southern Africa. Several strategies have the potential to reduce the burden of TB in high HIV prevalence settings, and cost and cost-effectiveness analyses can help to prioritize them when budget constraints exist. However, published cost and cost-effectiveness studies are limited. METHODS: Our objective was to compare the cost, affordability and cost-effectiveness of seven strategies for reducing the burden of TB in countries with high HIV prevalence. A compartmental difference equation model of TB and HIV and recent cost data were used to assess the costs (year 2003 USD prices) and effects (TB cases averted, deaths averted, DALYs gained) of these strategies in Kenya during the period 2004-2023. RESULTS: The three lowest cost and most cost-effective strategies were improving TB cure rates, improving TB case detection rates, and improving both together. The incremental cost of combined improvements to case detection and cure was below USD 15 million per year (7.5% of year 2000 government health expenditure); the mean cost per DALY gained of these three strategies ranged from USD 18 to USD 34. Antiretroviral therapy (ART) had the highest incremental costs, which by 2007 could be as large as total government health expenditures in year 2000. ART could also gain more DALYs than the other strategies, at a cost per DALY gained of around USD 260 to USD 530. Both the costs and effects of treatment for latent tuberculosis infection (TLTI) for HIV+ individuals were low; the cost per DALY gained ranged from about USD 85 to USD 370. Averting one HIV infection for less than USD 250 would be as cost-effective as improving TB case detection and cure rates to WHO target levels. CONCLUSION: To reduce the burden of TB in high HIV prevalence settings, the immediate goal should be to increase TB case detection rates and, to the extent possible, improve TB cure rates, preferably in combination. Realising the full potential of ART will require substantial new funding and strengthening of health system capacity so that increased funding can be used effectively.",2005-99-01564,16343345,BMC Public Health,Christine S M Currie,2012,12 /,130,No,16343345,"Christine S M Currie; Katherine Floyd; Brian G Williams; Christopher Dye; Katherine Floyd; Brian G Williams; Christopher Dye; Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence, BMC Public Health, ; 12():1471-2458; 130",DALY,Kenya,Not Stated,"Diagnostic, Pharmaceutical",Improving TB case detection rates to detect 70% of new smear positive cases vs. None,Area with high HIV prevalence,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,13,United States,2003,18.29
26109,"Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence","BACKGROUND: The HIV epidemic has caused a dramatic increase in tuberculosis (TB) in East and southern Africa. Several strategies have the potential to reduce the burden of TB in high HIV prevalence settings, and cost and cost-effectiveness analyses can help to prioritize them when budget constraints exist. However, published cost and cost-effectiveness studies are limited. METHODS: Our objective was to compare the cost, affordability and cost-effectiveness of seven strategies for reducing the burden of TB in countries with high HIV prevalence. A compartmental difference equation model of TB and HIV and recent cost data were used to assess the costs (year 2003 USD prices) and effects (TB cases averted, deaths averted, DALYs gained) of these strategies in Kenya during the period 2004-2023. RESULTS: The three lowest cost and most cost-effective strategies were improving TB cure rates, improving TB case detection rates, and improving both together. The incremental cost of combined improvements to case detection and cure was below USD 15 million per year (7.5% of year 2000 government health expenditure); the mean cost per DALY gained of these three strategies ranged from USD 18 to USD 34. Antiretroviral therapy (ART) had the highest incremental costs, which by 2007 could be as large as total government health expenditures in year 2000. ART could also gain more DALYs than the other strategies, at a cost per DALY gained of around USD 260 to USD 530. Both the costs and effects of treatment for latent tuberculosis infection (TLTI) for HIV+ individuals were low; the cost per DALY gained ranged from about USD 85 to USD 370. Averting one HIV infection for less than USD 250 would be as cost-effective as improving TB case detection and cure rates to WHO target levels. CONCLUSION: To reduce the burden of TB in high HIV prevalence settings, the immediate goal should be to increase TB case detection rates and, to the extent possible, improve TB cure rates, preferably in combination. Realising the full potential of ART will require substantial new funding and strengthening of health system capacity so that increased funding can be used effectively.",2005-99-01564,16343345,BMC Public Health,Christine S M Currie,2012,12 /,130,No,16343345,"Christine S M Currie; Katherine Floyd; Brian G Williams; Christopher Dye; Katherine Floyd; Brian G Williams; Christopher Dye; Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence, BMC Public Health, ; 12():1471-2458; 130",DALY,Kenya,Not Stated,"Diagnostic, Pharmaceutical",Improving TB cure rates to 85% vs. None,Area with high HIV prevalence,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,25,United States,2003,35.16
26110,"Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence","BACKGROUND: The HIV epidemic has caused a dramatic increase in tuberculosis (TB) in East and southern Africa. Several strategies have the potential to reduce the burden of TB in high HIV prevalence settings, and cost and cost-effectiveness analyses can help to prioritize them when budget constraints exist. However, published cost and cost-effectiveness studies are limited. METHODS: Our objective was to compare the cost, affordability and cost-effectiveness of seven strategies for reducing the burden of TB in countries with high HIV prevalence. A compartmental difference equation model of TB and HIV and recent cost data were used to assess the costs (year 2003 USD prices) and effects (TB cases averted, deaths averted, DALYs gained) of these strategies in Kenya during the period 2004-2023. RESULTS: The three lowest cost and most cost-effective strategies were improving TB cure rates, improving TB case detection rates, and improving both together. The incremental cost of combined improvements to case detection and cure was below USD 15 million per year (7.5% of year 2000 government health expenditure); the mean cost per DALY gained of these three strategies ranged from USD 18 to USD 34. Antiretroviral therapy (ART) had the highest incremental costs, which by 2007 could be as large as total government health expenditures in year 2000. ART could also gain more DALYs than the other strategies, at a cost per DALY gained of around USD 260 to USD 530. Both the costs and effects of treatment for latent tuberculosis infection (TLTI) for HIV+ individuals were low; the cost per DALY gained ranged from about USD 85 to USD 370. Averting one HIV infection for less than USD 250 would be as cost-effective as improving TB case detection and cure rates to WHO target levels. CONCLUSION: To reduce the burden of TB in high HIV prevalence settings, the immediate goal should be to increase TB case detection rates and, to the extent possible, improve TB cure rates, preferably in combination. Realising the full potential of ART will require substantial new funding and strengthening of health system capacity so that increased funding can be used effectively.",2005-99-01564,16343345,BMC Public Health,Christine S M Currie,2012,12 /,130,No,16343345,"Christine S M Currie; Katherine Floyd; Brian G Williams; Christopher Dye; Katherine Floyd; Brian G Williams; Christopher Dye; Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence, BMC Public Health, ; 12():1471-2458; 130",DALY,Kenya,Not Stated,"Diagnostic, Pharmaceutical",Improving TB case detection and cure rates simultaneously vs. None,Area with high HIV prevalence,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,10,United States,2003,14.07
26111,"Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence","BACKGROUND: The HIV epidemic has caused a dramatic increase in tuberculosis (TB) in East and southern Africa. Several strategies have the potential to reduce the burden of TB in high HIV prevalence settings, and cost and cost-effectiveness analyses can help to prioritize them when budget constraints exist. However, published cost and cost-effectiveness studies are limited. METHODS: Our objective was to compare the cost, affordability and cost-effectiveness of seven strategies for reducing the burden of TB in countries with high HIV prevalence. A compartmental difference equation model of TB and HIV and recent cost data were used to assess the costs (year 2003 USD prices) and effects (TB cases averted, deaths averted, DALYs gained) of these strategies in Kenya during the period 2004-2023. RESULTS: The three lowest cost and most cost-effective strategies were improving TB cure rates, improving TB case detection rates, and improving both together. The incremental cost of combined improvements to case detection and cure was below USD 15 million per year (7.5% of year 2000 government health expenditure); the mean cost per DALY gained of these three strategies ranged from USD 18 to USD 34. Antiretroviral therapy (ART) had the highest incremental costs, which by 2007 could be as large as total government health expenditures in year 2000. ART could also gain more DALYs than the other strategies, at a cost per DALY gained of around USD 260 to USD 530. Both the costs and effects of treatment for latent tuberculosis infection (TLTI) for HIV+ individuals were low; the cost per DALY gained ranged from about USD 85 to USD 370. Averting one HIV infection for less than USD 250 would be as cost-effective as improving TB case detection and cure rates to WHO target levels. CONCLUSION: To reduce the burden of TB in high HIV prevalence settings, the immediate goal should be to increase TB case detection rates and, to the extent possible, improve TB cure rates, preferably in combination. Realising the full potential of ART will require substantial new funding and strengthening of health system capacity so that increased funding can be used effectively.",2005-99-01564,16343345,BMC Public Health,Christine S M Currie,2012,12 /,130,No,16343345,"Christine S M Currie; Katherine Floyd; Brian G Williams; Christopher Dye; Katherine Floyd; Brian G Williams; Christopher Dye; Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence, BMC Public Health, ; 12():1471-2458; 130",DALY,Kenya,Not Stated,"Diagnostic, Pharmaceutical",Offering a six-month course of treatment for latent TB infection vs. None,Area with high HIV prevalence; HIV-positive; ot have tuberculosis,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,52,United States,2003,73.14
26112,"Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence","BACKGROUND: The HIV epidemic has caused a dramatic increase in tuberculosis (TB) in East and southern Africa. Several strategies have the potential to reduce the burden of TB in high HIV prevalence settings, and cost and cost-effectiveness analyses can help to prioritize them when budget constraints exist. However, published cost and cost-effectiveness studies are limited. METHODS: Our objective was to compare the cost, affordability and cost-effectiveness of seven strategies for reducing the burden of TB in countries with high HIV prevalence. A compartmental difference equation model of TB and HIV and recent cost data were used to assess the costs (year 2003 USD prices) and effects (TB cases averted, deaths averted, DALYs gained) of these strategies in Kenya during the period 2004-2023. RESULTS: The three lowest cost and most cost-effective strategies were improving TB cure rates, improving TB case detection rates, and improving both together. The incremental cost of combined improvements to case detection and cure was below USD 15 million per year (7.5% of year 2000 government health expenditure); the mean cost per DALY gained of these three strategies ranged from USD 18 to USD 34. Antiretroviral therapy (ART) had the highest incremental costs, which by 2007 could be as large as total government health expenditures in year 2000. ART could also gain more DALYs than the other strategies, at a cost per DALY gained of around USD 260 to USD 530. Both the costs and effects of treatment for latent tuberculosis infection (TLTI) for HIV+ individuals were low; the cost per DALY gained ranged from about USD 85 to USD 370. Averting one HIV infection for less than USD 250 would be as cost-effective as improving TB case detection and cure rates to WHO target levels. CONCLUSION: To reduce the burden of TB in high HIV prevalence settings, the immediate goal should be to increase TB case detection rates and, to the extent possible, improve TB cure rates, preferably in combination. Realising the full potential of ART will require substantial new funding and strengthening of health system capacity so that increased funding can be used effectively.",2005-99-01564,16343345,BMC Public Health,Christine S M Currie,2012,12 /,130,No,16343345,"Christine S M Currie; Katherine Floyd; Brian G Williams; Christopher Dye; Katherine Floyd; Brian G Williams; Christopher Dye; Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence, BMC Public Health, ; 12():1471-2458; 130",DALY,Kenya,Not Stated,"Diagnostic, Pharmaceutical",Antiretroviral therapy vs. None,Area with high HIV prevalence,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,254,United States,2003,357.27
26113,"Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence","BACKGROUND: The HIV epidemic has caused a dramatic increase in tuberculosis (TB) in East and southern Africa. Several strategies have the potential to reduce the burden of TB in high HIV prevalence settings, and cost and cost-effectiveness analyses can help to prioritize them when budget constraints exist. However, published cost and cost-effectiveness studies are limited. METHODS: Our objective was to compare the cost, affordability and cost-effectiveness of seven strategies for reducing the burden of TB in countries with high HIV prevalence. A compartmental difference equation model of TB and HIV and recent cost data were used to assess the costs (year 2003 USD prices) and effects (TB cases averted, deaths averted, DALYs gained) of these strategies in Kenya during the period 2004-2023. RESULTS: The three lowest cost and most cost-effective strategies were improving TB cure rates, improving TB case detection rates, and improving both together. The incremental cost of combined improvements to case detection and cure was below USD 15 million per year (7.5% of year 2000 government health expenditure); the mean cost per DALY gained of these three strategies ranged from USD 18 to USD 34. Antiretroviral therapy (ART) had the highest incremental costs, which by 2007 could be as large as total government health expenditures in year 2000. ART could also gain more DALYs than the other strategies, at a cost per DALY gained of around USD 260 to USD 530. Both the costs and effects of treatment for latent tuberculosis infection (TLTI) for HIV+ individuals were low; the cost per DALY gained ranged from about USD 85 to USD 370. Averting one HIV infection for less than USD 250 would be as cost-effective as improving TB case detection and cure rates to WHO target levels. CONCLUSION: To reduce the burden of TB in high HIV prevalence settings, the immediate goal should be to increase TB case detection rates and, to the extent possible, improve TB cure rates, preferably in combination. Realising the full potential of ART will require substantial new funding and strengthening of health system capacity so that increased funding can be used effectively.",2005-99-01564,16343345,BMC Public Health,Christine S M Currie,2012,12 /,130,No,16343345,"Christine S M Currie; Katherine Floyd; Brian G Williams; Christopher Dye; Katherine Floyd; Brian G Williams; Christopher Dye; Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence, BMC Public Health, ; 12():1471-2458; 130",DALY,Kenya,Not Stated,"Diagnostic, Pharmaceutical",Antiretroviral therapy vs. None,Area with high HIV prevalence,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,447,United States,2003,628.74
26114,Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder,"Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal disease burden.To estimate the cost-effectiveness of interventions for reducing the global burden of bipolar disorder.Hospital- and community-based delivery of two generic mood stabilisers (lithium and valproic acid), alone and in combination with psychosocial treatment, were modelled for 14 global sub-regions. A population model was employed to estimate the impact of different strategies, relative to no intervention. Total costs (in international dollars (I$)) and effectiveness (disability-adjusted life years (DALYs) averted) were combined to form cost-effectiveness ratios.Baseline results showed lithium to be no more costly yet more effective than valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. Community-based treatment with lithium and psychosocial care was most cost-effective (cost per DALY averted: I$2165-6475 in developing sub-regions; I$5487-21123 in developed sub-regions).Community-based interventions for bipolar disorder were estimated to be more efficient than hospital-based services, each DALY averted costing between one and three times average gross national income.",2005-99-12446,16319409,Br J Psychiatry,Dan Chisholm,2005,187 /,559-67,No,16319409,"Dan Chisholm; Mark van Ommeren; Jose-Luis Ayuso-Mateos; Shekhar Saxena; Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder, Br J Psychiatry, ; 187():0007-1250; 559-67",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Lithium vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,3234,United States,2003,4548.88
26115,Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder,"Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal disease burden.To estimate the cost-effectiveness of interventions for reducing the global burden of bipolar disorder.Hospital- and community-based delivery of two generic mood stabilisers (lithium and valproic acid), alone and in combination with psychosocial treatment, were modelled for 14 global sub-regions. A population model was employed to estimate the impact of different strategies, relative to no intervention. Total costs (in international dollars (I$)) and effectiveness (disability-adjusted life years (DALYs) averted) were combined to form cost-effectiveness ratios.Baseline results showed lithium to be no more costly yet more effective than valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. Community-based treatment with lithium and psychosocial care was most cost-effective (cost per DALY averted: I$2165-6475 in developing sub-regions; I$5487-21123 in developed sub-regions).Community-based interventions for bipolar disorder were estimated to be more efficient than hospital-based services, each DALY averted costing between one and three times average gross national income.",2005-99-12446,16319409,Br J Psychiatry,Dan Chisholm,2005,187 /,559-67,No,16319409,"Dan Chisholm; Mark van Ommeren; Jose-Luis Ayuso-Mateos; Shekhar Saxena; Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder, Br J Psychiatry, ; 187():0007-1250; 559-67",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Valproic acid vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,4457,United States,2003,6269.13
26116,Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder,"Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal disease burden.To estimate the cost-effectiveness of interventions for reducing the global burden of bipolar disorder.Hospital- and community-based delivery of two generic mood stabilisers (lithium and valproic acid), alone and in combination with psychosocial treatment, were modelled for 14 global sub-regions. A population model was employed to estimate the impact of different strategies, relative to no intervention. Total costs (in international dollars (I$)) and effectiveness (disability-adjusted life years (DALYs) averted) were combined to form cost-effectiveness ratios.Baseline results showed lithium to be no more costly yet more effective than valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. Community-based treatment with lithium and psychosocial care was most cost-effective (cost per DALY averted: I$2165-6475 in developing sub-regions; I$5487-21123 in developed sub-regions).Community-based interventions for bipolar disorder were estimated to be more efficient than hospital-based services, each DALY averted costing between one and three times average gross national income.",2005-99-12446,16319409,Br J Psychiatry,Dan Chisholm,2005,187 /,559-67,No,16319409,"Dan Chisholm; Mark van Ommeren; Jose-Luis Ayuso-Mateos; Shekhar Saxena; Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder, Br J Psychiatry, ; 187():0007-1250; 559-67",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Lithium + psychosocial vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,3063,United States,2003,4308.36
26117,Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder,"Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal disease burden.To estimate the cost-effectiveness of interventions for reducing the global burden of bipolar disorder.Hospital- and community-based delivery of two generic mood stabilisers (lithium and valproic acid), alone and in combination with psychosocial treatment, were modelled for 14 global sub-regions. A population model was employed to estimate the impact of different strategies, relative to no intervention. Total costs (in international dollars (I$)) and effectiveness (disability-adjusted life years (DALYs) averted) were combined to form cost-effectiveness ratios.Baseline results showed lithium to be no more costly yet more effective than valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. Community-based treatment with lithium and psychosocial care was most cost-effective (cost per DALY averted: I$2165-6475 in developing sub-regions; I$5487-21123 in developed sub-regions).Community-based interventions for bipolar disorder were estimated to be more efficient than hospital-based services, each DALY averted costing between one and three times average gross national income.",2005-99-12446,16319409,Br J Psychiatry,Dan Chisholm,2005,187 /,559-67,No,16319409,"Dan Chisholm; Mark van Ommeren; Jose-Luis Ayuso-Mateos; Shekhar Saxena; Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder, Br J Psychiatry, ; 187():0007-1250; 559-67",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Valproic acid + psychosocial vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,4142,United States,2003,5826.06
26118,Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder,"Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal disease burden.To estimate the cost-effectiveness of interventions for reducing the global burden of bipolar disorder.Hospital- and community-based delivery of two generic mood stabilisers (lithium and valproic acid), alone and in combination with psychosocial treatment, were modelled for 14 global sub-regions. A population model was employed to estimate the impact of different strategies, relative to no intervention. Total costs (in international dollars (I$)) and effectiveness (disability-adjusted life years (DALYs) averted) were combined to form cost-effectiveness ratios.Baseline results showed lithium to be no more costly yet more effective than valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. Community-based treatment with lithium and psychosocial care was most cost-effective (cost per DALY averted: I$2165-6475 in developing sub-regions; I$5487-21123 in developed sub-regions).Community-based interventions for bipolar disorder were estimated to be more efficient than hospital-based services, each DALY averted costing between one and three times average gross national income.",2005-99-12446,16319409,Br J Psychiatry,Dan Chisholm,2005,187 /,559-67,No,16319409,"Dan Chisholm; Mark van Ommeren; Jose-Luis Ayuso-Mateos; Shekhar Saxena; Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder, Br J Psychiatry, ; 187():0007-1250; 559-67",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Lithium vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,3307,United States,2003,4651.57
26119,Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder,"Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal disease burden.To estimate the cost-effectiveness of interventions for reducing the global burden of bipolar disorder.Hospital- and community-based delivery of two generic mood stabilisers (lithium and valproic acid), alone and in combination with psychosocial treatment, were modelled for 14 global sub-regions. A population model was employed to estimate the impact of different strategies, relative to no intervention. Total costs (in international dollars (I$)) and effectiveness (disability-adjusted life years (DALYs) averted) were combined to form cost-effectiveness ratios.Baseline results showed lithium to be no more costly yet more effective than valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. Community-based treatment with lithium and psychosocial care was most cost-effective (cost per DALY averted: I$2165-6475 in developing sub-regions; I$5487-21123 in developed sub-regions).Community-based interventions for bipolar disorder were estimated to be more efficient than hospital-based services, each DALY averted costing between one and three times average gross national income.",2005-99-12446,16319409,Br J Psychiatry,Dan Chisholm,2005,187 /,559-67,No,16319409,"Dan Chisholm; Mark van Ommeren; Jose-Luis Ayuso-Mateos; Shekhar Saxena; Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder, Br J Psychiatry, ; 187():0007-1250; 559-67",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Valproic acid vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,5017,United States,2003,7056.82
26120,Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder,"Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal disease burden.To estimate the cost-effectiveness of interventions for reducing the global burden of bipolar disorder.Hospital- and community-based delivery of two generic mood stabilisers (lithium and valproic acid), alone and in combination with psychosocial treatment, were modelled for 14 global sub-regions. A population model was employed to estimate the impact of different strategies, relative to no intervention. Total costs (in international dollars (I$)) and effectiveness (disability-adjusted life years (DALYs) averted) were combined to form cost-effectiveness ratios.Baseline results showed lithium to be no more costly yet more effective than valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. Community-based treatment with lithium and psychosocial care was most cost-effective (cost per DALY averted: I$2165-6475 in developing sub-regions; I$5487-21123 in developed sub-regions).Community-based interventions for bipolar disorder were estimated to be more efficient than hospital-based services, each DALY averted costing between one and three times average gross national income.",2005-99-12446,16319409,Br J Psychiatry,Dan Chisholm,2005,187 /,559-67,No,16319409,"Dan Chisholm; Mark van Ommeren; Jose-Luis Ayuso-Mateos; Shekhar Saxena; Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder, Br J Psychiatry, ; 187():0007-1250; 559-67",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Lithium + psychosocial vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,3145,United States,2003,4423.7
26121,Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder,"Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal disease burden.To estimate the cost-effectiveness of interventions for reducing the global burden of bipolar disorder.Hospital- and community-based delivery of two generic mood stabilisers (lithium and valproic acid), alone and in combination with psychosocial treatment, were modelled for 14 global sub-regions. A population model was employed to estimate the impact of different strategies, relative to no intervention. Total costs (in international dollars (I$)) and effectiveness (disability-adjusted life years (DALYs) averted) were combined to form cost-effectiveness ratios.Baseline results showed lithium to be no more costly yet more effective than valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. Community-based treatment with lithium and psychosocial care was most cost-effective (cost per DALY averted: I$2165-6475 in developing sub-regions; I$5487-21123 in developed sub-regions).Community-based interventions for bipolar disorder were estimated to be more efficient than hospital-based services, each DALY averted costing between one and three times average gross national income.",2005-99-12446,16319409,Br J Psychiatry,Dan Chisholm,2005,187 /,559-67,No,16319409,"Dan Chisholm; Mark van Ommeren; Jose-Luis Ayuso-Mateos; Shekhar Saxena; Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder, Br J Psychiatry, ; 187():0007-1250; 559-67",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Valproic acid + psychosocial vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,4652,United States,2003,6543.42
26122,Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder,"Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal disease burden.To estimate the cost-effectiveness of interventions for reducing the global burden of bipolar disorder.Hospital- and community-based delivery of two generic mood stabilisers (lithium and valproic acid), alone and in combination with psychosocial treatment, were modelled for 14 global sub-regions. A population model was employed to estimate the impact of different strategies, relative to no intervention. Total costs (in international dollars (I$)) and effectiveness (disability-adjusted life years (DALYs) averted) were combined to form cost-effectiveness ratios.Baseline results showed lithium to be no more costly yet more effective than valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. Community-based treatment with lithium and psychosocial care was most cost-effective (cost per DALY averted: I$2165-6475 in developing sub-regions; I$5487-21123 in developed sub-regions).Community-based interventions for bipolar disorder were estimated to be more efficient than hospital-based services, each DALY averted costing between one and three times average gross national income.",2005-99-12446,16319409,Br J Psychiatry,Dan Chisholm,2005,187 /,559-67,No,16319409,"Dan Chisholm; Mark van Ommeren; Jose-Luis Ayuso-Mateos; Shekhar Saxena; Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder, Br J Psychiatry, ; 187():0007-1250; 559-67",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Lithium vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,38332,United States,2003,53917.08
26123,Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder,"Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal disease burden.To estimate the cost-effectiveness of interventions for reducing the global burden of bipolar disorder.Hospital- and community-based delivery of two generic mood stabilisers (lithium and valproic acid), alone and in combination with psychosocial treatment, were modelled for 14 global sub-regions. A population model was employed to estimate the impact of different strategies, relative to no intervention. Total costs (in international dollars (I$)) and effectiveness (disability-adjusted life years (DALYs) averted) were combined to form cost-effectiveness ratios.Baseline results showed lithium to be no more costly yet more effective than valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. Community-based treatment with lithium and psychosocial care was most cost-effective (cost per DALY averted: I$2165-6475 in developing sub-regions; I$5487-21123 in developed sub-regions).Community-based interventions for bipolar disorder were estimated to be more efficient than hospital-based services, each DALY averted costing between one and three times average gross national income.",2005-99-12446,16319409,Br J Psychiatry,Dan Chisholm,2005,187 /,559-67,No,16319409,"Dan Chisholm; Mark van Ommeren; Jose-Luis Ayuso-Mateos; Shekhar Saxena; Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder, Br J Psychiatry, ; 187():0007-1250; 559-67",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Valproic acid vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,39295,United States,2003,55271.62
26124,Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder,"Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal disease burden.To estimate the cost-effectiveness of interventions for reducing the global burden of bipolar disorder.Hospital- and community-based delivery of two generic mood stabilisers (lithium and valproic acid), alone and in combination with psychosocial treatment, were modelled for 14 global sub-regions. A population model was employed to estimate the impact of different strategies, relative to no intervention. Total costs (in international dollars (I$)) and effectiveness (disability-adjusted life years (DALYs) averted) were combined to form cost-effectiveness ratios.Baseline results showed lithium to be no more costly yet more effective than valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. Community-based treatment with lithium and psychosocial care was most cost-effective (cost per DALY averted: I$2165-6475 in developing sub-regions; I$5487-21123 in developed sub-regions).Community-based interventions for bipolar disorder were estimated to be more efficient than hospital-based services, each DALY averted costing between one and three times average gross national income.",2005-99-12446,16319409,Br J Psychiatry,Dan Chisholm,2005,187 /,559-67,No,16319409,"Dan Chisholm; Mark van Ommeren; Jose-Luis Ayuso-Mateos; Shekhar Saxena; Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder, Br J Psychiatry, ; 187():0007-1250; 559-67",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Lithium + psychosocial vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,35606,United States,2003,50082.74
26125,Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder,"Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal disease burden.To estimate the cost-effectiveness of interventions for reducing the global burden of bipolar disorder.Hospital- and community-based delivery of two generic mood stabilisers (lithium and valproic acid), alone and in combination with psychosocial treatment, were modelled for 14 global sub-regions. A population model was employed to estimate the impact of different strategies, relative to no intervention. Total costs (in international dollars (I$)) and effectiveness (disability-adjusted life years (DALYs) averted) were combined to form cost-effectiveness ratios.Baseline results showed lithium to be no more costly yet more effective than valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. Community-based treatment with lithium and psychosocial care was most cost-effective (cost per DALY averted: I$2165-6475 in developing sub-regions; I$5487-21123 in developed sub-regions).Community-based interventions for bipolar disorder were estimated to be more efficient than hospital-based services, each DALY averted costing between one and three times average gross national income.",2005-99-12446,16319409,Br J Psychiatry,Dan Chisholm,2005,187 /,559-67,No,16319409,"Dan Chisholm; Mark van Ommeren; Jose-Luis Ayuso-Mateos; Shekhar Saxena; Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder, Br J Psychiatry, ; 187():0007-1250; 559-67",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Valproic acid + psychosocial vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,36398,United States,2003,51196.75
26126,Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder,"Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal disease burden.To estimate the cost-effectiveness of interventions for reducing the global burden of bipolar disorder.Hospital- and community-based delivery of two generic mood stabilisers (lithium and valproic acid), alone and in combination with psychosocial treatment, were modelled for 14 global sub-regions. A population model was employed to estimate the impact of different strategies, relative to no intervention. Total costs (in international dollars (I$)) and effectiveness (disability-adjusted life years (DALYs) averted) were combined to form cost-effectiveness ratios.Baseline results showed lithium to be no more costly yet more effective than valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. Community-based treatment with lithium and psychosocial care was most cost-effective (cost per DALY averted: I$2165-6475 in developing sub-regions; I$5487-21123 in developed sub-regions).Community-based interventions for bipolar disorder were estimated to be more efficient than hospital-based services, each DALY averted costing between one and three times average gross national income.",2005-99-12446,16319409,Br J Psychiatry,Dan Chisholm,2005,187 /,559-67,No,16319409,"Dan Chisholm; Mark van Ommeren; Jose-Luis Ayuso-Mateos; Shekhar Saxena; Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder, Br J Psychiatry, ; 187():0007-1250; 559-67",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Lithium vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,12205,United States,2003,17167.33
26127,Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder,"Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal disease burden.To estimate the cost-effectiveness of interventions for reducing the global burden of bipolar disorder.Hospital- and community-based delivery of two generic mood stabilisers (lithium and valproic acid), alone and in combination with psychosocial treatment, were modelled for 14 global sub-regions. A population model was employed to estimate the impact of different strategies, relative to no intervention. Total costs (in international dollars (I$)) and effectiveness (disability-adjusted life years (DALYs) averted) were combined to form cost-effectiveness ratios.Baseline results showed lithium to be no more costly yet more effective than valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. Community-based treatment with lithium and psychosocial care was most cost-effective (cost per DALY averted: I$2165-6475 in developing sub-regions; I$5487-21123 in developed sub-regions).Community-based interventions for bipolar disorder were estimated to be more efficient than hospital-based services, each DALY averted costing between one and three times average gross national income.",2005-99-12446,16319409,Br J Psychiatry,Dan Chisholm,2005,187 /,559-67,No,16319409,"Dan Chisholm; Mark van Ommeren; Jose-Luis Ayuso-Mateos; Shekhar Saxena; Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder, Br J Psychiatry, ; 187():0007-1250; 559-67",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Valproic acid vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,13194,United States,2003,18558.44
26128,Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder,"Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal disease burden.To estimate the cost-effectiveness of interventions for reducing the global burden of bipolar disorder.Hospital- and community-based delivery of two generic mood stabilisers (lithium and valproic acid), alone and in combination with psychosocial treatment, were modelled for 14 global sub-regions. A population model was employed to estimate the impact of different strategies, relative to no intervention. Total costs (in international dollars (I$)) and effectiveness (disability-adjusted life years (DALYs) averted) were combined to form cost-effectiveness ratios.Baseline results showed lithium to be no more costly yet more effective than valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. Community-based treatment with lithium and psychosocial care was most cost-effective (cost per DALY averted: I$2165-6475 in developing sub-regions; I$5487-21123 in developed sub-regions).Community-based interventions for bipolar disorder were estimated to be more efficient than hospital-based services, each DALY averted costing between one and three times average gross national income.",2005-99-12446,16319409,Br J Psychiatry,Dan Chisholm,2005,187 /,559-67,No,16319409,"Dan Chisholm; Mark van Ommeren; Jose-Luis Ayuso-Mateos; Shekhar Saxena; Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder, Br J Psychiatry, ; 187():0007-1250; 559-67",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Lithium + psychosocial vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,11001,United States,2003,15473.8
26129,Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder,"Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal disease burden.To estimate the cost-effectiveness of interventions for reducing the global burden of bipolar disorder.Hospital- and community-based delivery of two generic mood stabilisers (lithium and valproic acid), alone and in combination with psychosocial treatment, were modelled for 14 global sub-regions. A population model was employed to estimate the impact of different strategies, relative to no intervention. Total costs (in international dollars (I$)) and effectiveness (disability-adjusted life years (DALYs) averted) were combined to form cost-effectiveness ratios.Baseline results showed lithium to be no more costly yet more effective than valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. Community-based treatment with lithium and psychosocial care was most cost-effective (cost per DALY averted: I$2165-6475 in developing sub-regions; I$5487-21123 in developed sub-regions).Community-based interventions for bipolar disorder were estimated to be more efficient than hospital-based services, each DALY averted costing between one and three times average gross national income.",2005-99-12446,16319409,Br J Psychiatry,Dan Chisholm,2005,187 /,559-67,No,16319409,"Dan Chisholm; Mark van Ommeren; Jose-Luis Ayuso-Mateos; Shekhar Saxena; Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder, Br J Psychiatry, ; 187():0007-1250; 559-67",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Valproic acid + psychosocial vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,11832,United States,2003,16642.67
26130,Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder,"Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal disease burden.To estimate the cost-effectiveness of interventions for reducing the global burden of bipolar disorder.Hospital- and community-based delivery of two generic mood stabilisers (lithium and valproic acid), alone and in combination with psychosocial treatment, were modelled for 14 global sub-regions. A population model was employed to estimate the impact of different strategies, relative to no intervention. Total costs (in international dollars (I$)) and effectiveness (disability-adjusted life years (DALYs) averted) were combined to form cost-effectiveness ratios.Baseline results showed lithium to be no more costly yet more effective than valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. Community-based treatment with lithium and psychosocial care was most cost-effective (cost per DALY averted: I$2165-6475 in developing sub-regions; I$5487-21123 in developed sub-regions).Community-based interventions for bipolar disorder were estimated to be more efficient than hospital-based services, each DALY averted costing between one and three times average gross national income.",2005-99-12446,16319409,Br J Psychiatry,Dan Chisholm,2005,187 /,559-67,No,16319409,"Dan Chisholm; Mark van Ommeren; Jose-Luis Ayuso-Mateos; Shekhar Saxena; Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder, Br J Psychiatry, ; 187():0007-1250; 559-67",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Lithium vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,6878,United States,2003,9674.47
26131,Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder,"Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal disease burden.To estimate the cost-effectiveness of interventions for reducing the global burden of bipolar disorder.Hospital- and community-based delivery of two generic mood stabilisers (lithium and valproic acid), alone and in combination with psychosocial treatment, were modelled for 14 global sub-regions. A population model was employed to estimate the impact of different strategies, relative to no intervention. Total costs (in international dollars (I$)) and effectiveness (disability-adjusted life years (DALYs) averted) were combined to form cost-effectiveness ratios.Baseline results showed lithium to be no more costly yet more effective than valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. Community-based treatment with lithium and psychosocial care was most cost-effective (cost per DALY averted: I$2165-6475 in developing sub-regions; I$5487-21123 in developed sub-regions).Community-based interventions for bipolar disorder were estimated to be more efficient than hospital-based services, each DALY averted costing between one and three times average gross national income.",2005-99-12446,16319409,Br J Psychiatry,Dan Chisholm,2005,187 /,559-67,No,16319409,"Dan Chisholm; Mark van Ommeren; Jose-Luis Ayuso-Mateos; Shekhar Saxena; Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder, Br J Psychiatry, ; 187():0007-1250; 559-67",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Valproic acid vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,7819,United States,2003,10998.06
26132,Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder,"Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal disease burden.To estimate the cost-effectiveness of interventions for reducing the global burden of bipolar disorder.Hospital- and community-based delivery of two generic mood stabilisers (lithium and valproic acid), alone and in combination with psychosocial treatment, were modelled for 14 global sub-regions. A population model was employed to estimate the impact of different strategies, relative to no intervention. Total costs (in international dollars (I$)) and effectiveness (disability-adjusted life years (DALYs) averted) were combined to form cost-effectiveness ratios.Baseline results showed lithium to be no more costly yet more effective than valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. Community-based treatment with lithium and psychosocial care was most cost-effective (cost per DALY averted: I$2165-6475 in developing sub-regions; I$5487-21123 in developed sub-regions).Community-based interventions for bipolar disorder were estimated to be more efficient than hospital-based services, each DALY averted costing between one and three times average gross national income.",2005-99-12446,16319409,Br J Psychiatry,Dan Chisholm,2005,187 /,559-67,No,16319409,"Dan Chisholm; Mark van Ommeren; Jose-Luis Ayuso-Mateos; Shekhar Saxena; Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder, Br J Psychiatry, ; 187():0007-1250; 559-67",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Lithium+psychosocial vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,6268,United States,2003,8816.45
26133,Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder,"Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal disease burden.To estimate the cost-effectiveness of interventions for reducing the global burden of bipolar disorder.Hospital- and community-based delivery of two generic mood stabilisers (lithium and valproic acid), alone and in combination with psychosocial treatment, were modelled for 14 global sub-regions. A population model was employed to estimate the impact of different strategies, relative to no intervention. Total costs (in international dollars (I$)) and effectiveness (disability-adjusted life years (DALYs) averted) were combined to form cost-effectiveness ratios.Baseline results showed lithium to be no more costly yet more effective than valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. Community-based treatment with lithium and psychosocial care was most cost-effective (cost per DALY averted: I$2165-6475 in developing sub-regions; I$5487-21123 in developed sub-regions).Community-based interventions for bipolar disorder were estimated to be more efficient than hospital-based services, each DALY averted costing between one and three times average gross national income.",2005-99-12446,16319409,Br J Psychiatry,Dan Chisholm,2005,187 /,559-67,No,16319409,"Dan Chisholm; Mark van Ommeren; Jose-Luis Ayuso-Mateos; Shekhar Saxena; Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder, Br J Psychiatry, ; 187():0007-1250; 559-67",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Valproic acid + psychosocial vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,7077,United States,2003,9954.38
26134,Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder,"Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal disease burden.To estimate the cost-effectiveness of interventions for reducing the global burden of bipolar disorder.Hospital- and community-based delivery of two generic mood stabilisers (lithium and valproic acid), alone and in combination with psychosocial treatment, were modelled for 14 global sub-regions. A population model was employed to estimate the impact of different strategies, relative to no intervention. Total costs (in international dollars (I$)) and effectiveness (disability-adjusted life years (DALYs) averted) were combined to form cost-effectiveness ratios.Baseline results showed lithium to be no more costly yet more effective than valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. Community-based treatment with lithium and psychosocial care was most cost-effective (cost per DALY averted: I$2165-6475 in developing sub-regions; I$5487-21123 in developed sub-regions).Community-based interventions for bipolar disorder were estimated to be more efficient than hospital-based services, each DALY averted costing between one and three times average gross national income.",2005-99-12446,16319409,Br J Psychiatry,Dan Chisholm,2005,187 /,559-67,No,16319409,"Dan Chisholm; Mark van Ommeren; Jose-Luis Ayuso-Mateos; Shekhar Saxena; Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder, Br J Psychiatry, ; 187():0007-1250; 559-67",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Lithium vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,7138,United States,2003,10040.18
26135,Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder,"Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal disease burden.To estimate the cost-effectiveness of interventions for reducing the global burden of bipolar disorder.Hospital- and community-based delivery of two generic mood stabilisers (lithium and valproic acid), alone and in combination with psychosocial treatment, were modelled for 14 global sub-regions. A population model was employed to estimate the impact of different strategies, relative to no intervention. Total costs (in international dollars (I$)) and effectiveness (disability-adjusted life years (DALYs) averted) were combined to form cost-effectiveness ratios.Baseline results showed lithium to be no more costly yet more effective than valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. Community-based treatment with lithium and psychosocial care was most cost-effective (cost per DALY averted: I$2165-6475 in developing sub-regions; I$5487-21123 in developed sub-regions).Community-based interventions for bipolar disorder were estimated to be more efficient than hospital-based services, each DALY averted costing between one and three times average gross national income.",2005-99-12446,16319409,Br J Psychiatry,Dan Chisholm,2005,187 /,559-67,No,16319409,"Dan Chisholm; Mark van Ommeren; Jose-Luis Ayuso-Mateos; Shekhar Saxena; Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder, Br J Psychiatry, ; 187():0007-1250; 559-67",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Valproic acid vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,7656,United States,2003,10768.79
26136,Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder,"Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal disease burden.To estimate the cost-effectiveness of interventions for reducing the global burden of bipolar disorder.Hospital- and community-based delivery of two generic mood stabilisers (lithium and valproic acid), alone and in combination with psychosocial treatment, were modelled for 14 global sub-regions. A population model was employed to estimate the impact of different strategies, relative to no intervention. Total costs (in international dollars (I$)) and effectiveness (disability-adjusted life years (DALYs) averted) were combined to form cost-effectiveness ratios.Baseline results showed lithium to be no more costly yet more effective than valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. Community-based treatment with lithium and psychosocial care was most cost-effective (cost per DALY averted: I$2165-6475 in developing sub-regions; I$5487-21123 in developed sub-regions).Community-based interventions for bipolar disorder were estimated to be more efficient than hospital-based services, each DALY averted costing between one and three times average gross national income.",2005-99-12446,16319409,Br J Psychiatry,Dan Chisholm,2005,187 /,559-67,No,16319409,"Dan Chisholm; Mark van Ommeren; Jose-Luis Ayuso-Mateos; Shekhar Saxena; Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder, Br J Psychiatry, ; 187():0007-1250; 559-67",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Lithium+psychosocial vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,6516,United States,2003,9165.29
26137,Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder,"Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal disease burden.To estimate the cost-effectiveness of interventions for reducing the global burden of bipolar disorder.Hospital- and community-based delivery of two generic mood stabilisers (lithium and valproic acid), alone and in combination with psychosocial treatment, were modelled for 14 global sub-regions. A population model was employed to estimate the impact of different strategies, relative to no intervention. Total costs (in international dollars (I$)) and effectiveness (disability-adjusted life years (DALYs) averted) were combined to form cost-effectiveness ratios.Baseline results showed lithium to be no more costly yet more effective than valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. Community-based treatment with lithium and psychosocial care was most cost-effective (cost per DALY averted: I$2165-6475 in developing sub-regions; I$5487-21123 in developed sub-regions).Community-based interventions for bipolar disorder were estimated to be more efficient than hospital-based services, each DALY averted costing between one and three times average gross national income.",2005-99-12446,16319409,Br J Psychiatry,Dan Chisholm,2005,187 /,559-67,No,16319409,"Dan Chisholm; Mark van Ommeren; Jose-Luis Ayuso-Mateos; Shekhar Saxena; Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder, Br J Psychiatry, ; 187():0007-1250; 559-67",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Valproic acid + psychosocial vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,6971,United States,2003,9805.28
26138,Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder,"Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal disease burden.To estimate the cost-effectiveness of interventions for reducing the global burden of bipolar disorder.Hospital- and community-based delivery of two generic mood stabilisers (lithium and valproic acid), alone and in combination with psychosocial treatment, were modelled for 14 global sub-regions. A population model was employed to estimate the impact of different strategies, relative to no intervention. Total costs (in international dollars (I$)) and effectiveness (disability-adjusted life years (DALYs) averted) were combined to form cost-effectiveness ratios.Baseline results showed lithium to be no more costly yet more effective than valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. Community-based treatment with lithium and psychosocial care was most cost-effective (cost per DALY averted: I$2165-6475 in developing sub-regions; I$5487-21123 in developed sub-regions).Community-based interventions for bipolar disorder were estimated to be more efficient than hospital-based services, each DALY averted costing between one and three times average gross national income.",2005-99-12446,16319409,Br J Psychiatry,Dan Chisholm,2005,187 /,559-67,No,16319409,"Dan Chisholm; Mark van Ommeren; Jose-Luis Ayuso-Mateos; Shekhar Saxena; Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder, Br J Psychiatry, ; 187():0007-1250; 559-67",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Lithium vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,5243,United States,2003,7374.71
26139,Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder,"Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal disease burden.To estimate the cost-effectiveness of interventions for reducing the global burden of bipolar disorder.Hospital- and community-based delivery of two generic mood stabilisers (lithium and valproic acid), alone and in combination with psychosocial treatment, were modelled for 14 global sub-regions. A population model was employed to estimate the impact of different strategies, relative to no intervention. Total costs (in international dollars (I$)) and effectiveness (disability-adjusted life years (DALYs) averted) were combined to form cost-effectiveness ratios.Baseline results showed lithium to be no more costly yet more effective than valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. Community-based treatment with lithium and psychosocial care was most cost-effective (cost per DALY averted: I$2165-6475 in developing sub-regions; I$5487-21123 in developed sub-regions).Community-based interventions for bipolar disorder were estimated to be more efficient than hospital-based services, each DALY averted costing between one and three times average gross national income.",2005-99-12446,16319409,Br J Psychiatry,Dan Chisholm,2005,187 /,559-67,No,16319409,"Dan Chisholm; Mark van Ommeren; Jose-Luis Ayuso-Mateos; Shekhar Saxena; Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder, Br J Psychiatry, ; 187():0007-1250; 559-67",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Valproic acid vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,5893,United States,2003,8288.98
26140,Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder,"Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal disease burden.To estimate the cost-effectiveness of interventions for reducing the global burden of bipolar disorder.Hospital- and community-based delivery of two generic mood stabilisers (lithium and valproic acid), alone and in combination with psychosocial treatment, were modelled for 14 global sub-regions. A population model was employed to estimate the impact of different strategies, relative to no intervention. Total costs (in international dollars (I$)) and effectiveness (disability-adjusted life years (DALYs) averted) were combined to form cost-effectiveness ratios.Baseline results showed lithium to be no more costly yet more effective than valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. Community-based treatment with lithium and psychosocial care was most cost-effective (cost per DALY averted: I$2165-6475 in developing sub-regions; I$5487-21123 in developed sub-regions).Community-based interventions for bipolar disorder were estimated to be more efficient than hospital-based services, each DALY averted costing between one and three times average gross national income.",2005-99-12446,16319409,Br J Psychiatry,Dan Chisholm,2005,187 /,559-67,No,16319409,"Dan Chisholm; Mark van Ommeren; Jose-Luis Ayuso-Mateos; Shekhar Saxena; Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder, Br J Psychiatry, ; 187():0007-1250; 559-67",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Lithium + psychosocial vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,4800,United States,2003,6751.59
26141,Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder,"Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal disease burden.To estimate the cost-effectiveness of interventions for reducing the global burden of bipolar disorder.Hospital- and community-based delivery of two generic mood stabilisers (lithium and valproic acid), alone and in combination with psychosocial treatment, were modelled for 14 global sub-regions. A population model was employed to estimate the impact of different strategies, relative to no intervention. Total costs (in international dollars (I$)) and effectiveness (disability-adjusted life years (DALYs) averted) were combined to form cost-effectiveness ratios.Baseline results showed lithium to be no more costly yet more effective than valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. Community-based treatment with lithium and psychosocial care was most cost-effective (cost per DALY averted: I$2165-6475 in developing sub-regions; I$5487-21123 in developed sub-regions).Community-based interventions for bipolar disorder were estimated to be more efficient than hospital-based services, each DALY averted costing between one and three times average gross national income.",2005-99-12446,16319409,Br J Psychiatry,Dan Chisholm,2005,187 /,559-67,No,16319409,"Dan Chisholm; Mark van Ommeren; Jose-Luis Ayuso-Mateos; Shekhar Saxena; Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder, Br J Psychiatry, ; 187():0007-1250; 559-67",DALY,Not Stated,Not Stated,"Health Education or Behavior, Pharmaceutical",Valproic acid + psychosocial vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,5372,United States,2003,7556.16
26142,Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries,"OBJECTIVE: To determine the costs and benefits of interventions for maternal and newborn health to assess the appropriateness of current strategies and guide future plans to attain the millennium development goals. DESIGN: Cost effectiveness analysis. SETTING: Two regions classified by the World Health Organization according to their epidemiological grouping: Afr-E, those countries in sub-Saharan Africa with very high adult and high child mortality, and Sear-D, comprising countries in South East Asia with high adult and high child mortality. DATA SOURCES: Effectiveness data from several sources, including trials, observational studies, and expert opinion. For resource inputs, quantities came from WHO guidelines, literature, and expert opinion, and prices from the WHO choosing interventions that are cost effective database. MAIN OUTCOME MEASURES: Cost per disability adjusted life year (DALY) averted in year 2000 international dollars. RESULTS: The most cost effective mix of interventions was similar in Afr-E and Sear-D. These were the community based newborn care package, followed by antenatal care (tetanus toxoid, screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria and syphilis); skilled attendance at birth, offering first level maternal and neonatal care around childbirth; and emergency obstetric and neonatal care around and after birth. Screening and treatment of maternal syphilis, community based management of neonatal pneumonia, and steroids given during the antenatal period were relatively less cost effective in Sear-D. Scaling up all of the included interventions to 95% coverage would halve neonatal and maternal deaths. CONCLUSION: Preventive interventions at the community level for newborn babies and at the primary care level for mothers and newborn babies are extremely cost effective, but the millennium development goals for maternal and child health will not be achieved without universal access to clinical services as well.",2005-99-01607,16282407,BMJ,Taghreed Adam,2005,331 / 7525,1107,No,16282407,"Taghreed Adam; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries, BMJ, 2005-Nov-12; 331(7525):0959-8138; 1107",DALY,"Botswana, Burundi, Central African Republic, Congo Democratic Republic, Congo, Cte d'Ivoire, Eritrea, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe",Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Pharmaceutical, Screening",Community based management of neonatal pneumonia vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,1,United States,2000,1.5
26143,Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries,"OBJECTIVE: To determine the costs and benefits of interventions for maternal and newborn health to assess the appropriateness of current strategies and guide future plans to attain the millennium development goals. DESIGN: Cost effectiveness analysis. SETTING: Two regions classified by the World Health Organization according to their epidemiological grouping: Afr-E, those countries in sub-Saharan Africa with very high adult and high child mortality, and Sear-D, comprising countries in South East Asia with high adult and high child mortality. DATA SOURCES: Effectiveness data from several sources, including trials, observational studies, and expert opinion. For resource inputs, quantities came from WHO guidelines, literature, and expert opinion, and prices from the WHO choosing interventions that are cost effective database. MAIN OUTCOME MEASURES: Cost per disability adjusted life year (DALY) averted in year 2000 international dollars. RESULTS: The most cost effective mix of interventions was similar in Afr-E and Sear-D. These were the community based newborn care package, followed by antenatal care (tetanus toxoid, screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria and syphilis); skilled attendance at birth, offering first level maternal and neonatal care around childbirth; and emergency obstetric and neonatal care around and after birth. Screening and treatment of maternal syphilis, community based management of neonatal pneumonia, and steroids given during the antenatal period were relatively less cost effective in Sear-D. Scaling up all of the included interventions to 95% coverage would halve neonatal and maternal deaths. CONCLUSION: Preventive interventions at the community level for newborn babies and at the primary care level for mothers and newborn babies are extremely cost effective, but the millennium development goals for maternal and child health will not be achieved without universal access to clinical services as well.",2005-99-01607,16282407,BMJ,Taghreed Adam,2005,331 / 7525,1107,No,16282407,"Taghreed Adam; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries, BMJ, 2005-Nov-12; 331(7525):0959-8138; 1107",DALY,"Botswana, Burundi, Central African Republic, Congo Democratic Republic, Congo, Cte d'Ivoire, Eritrea, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe",Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Pharmaceutical, Screening",Community based management of neonatal pneumonia + community newborn care package vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,8,United States,2000,12.02
26144,Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries,"OBJECTIVE: To determine the costs and benefits of interventions for maternal and newborn health to assess the appropriateness of current strategies and guide future plans to attain the millennium development goals. DESIGN: Cost effectiveness analysis. SETTING: Two regions classified by the World Health Organization according to their epidemiological grouping: Afr-E, those countries in sub-Saharan Africa with very high adult and high child mortality, and Sear-D, comprising countries in South East Asia with high adult and high child mortality. DATA SOURCES: Effectiveness data from several sources, including trials, observational studies, and expert opinion. For resource inputs, quantities came from WHO guidelines, literature, and expert opinion, and prices from the WHO choosing interventions that are cost effective database. MAIN OUTCOME MEASURES: Cost per disability adjusted life year (DALY) averted in year 2000 international dollars. RESULTS: The most cost effective mix of interventions was similar in Afr-E and Sear-D. These were the community based newborn care package, followed by antenatal care (tetanus toxoid, screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria and syphilis); skilled attendance at birth, offering first level maternal and neonatal care around childbirth; and emergency obstetric and neonatal care around and after birth. Screening and treatment of maternal syphilis, community based management of neonatal pneumonia, and steroids given during the antenatal period were relatively less cost effective in Sear-D. Scaling up all of the included interventions to 95% coverage would halve neonatal and maternal deaths. CONCLUSION: Preventive interventions at the community level for newborn babies and at the primary care level for mothers and newborn babies are extremely cost effective, but the millennium development goals for maternal and child health will not be achieved without universal access to clinical services as well.",2005-99-01607,16282407,BMJ,Taghreed Adam,2005,331 / 7525,1107,No,16282407,"Taghreed Adam; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries, BMJ, 2005-Nov-12; 331(7525):0959-8138; 1107",DALY,"Botswana, Burundi, Central African Republic, Congo Democratic Republic, Congo, Cte d'Ivoire, Eritrea, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe",Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Pharmaceutical, Screening",Community based management of neonatal pneumonia + community newborn care package + tetanus toxoid vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,22,United States,2000,33.07
26145,Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries,"OBJECTIVE: To determine the costs and benefits of interventions for maternal and newborn health to assess the appropriateness of current strategies and guide future plans to attain the millennium development goals. DESIGN: Cost effectiveness analysis. SETTING: Two regions classified by the World Health Organization according to their epidemiological grouping: Afr-E, those countries in sub-Saharan Africa with very high adult and high child mortality, and Sear-D, comprising countries in South East Asia with high adult and high child mortality. DATA SOURCES: Effectiveness data from several sources, including trials, observational studies, and expert opinion. For resource inputs, quantities came from WHO guidelines, literature, and expert opinion, and prices from the WHO choosing interventions that are cost effective database. MAIN OUTCOME MEASURES: Cost per disability adjusted life year (DALY) averted in year 2000 international dollars. RESULTS: The most cost effective mix of interventions was similar in Afr-E and Sear-D. These were the community based newborn care package, followed by antenatal care (tetanus toxoid, screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria and syphilis); skilled attendance at birth, offering first level maternal and neonatal care around childbirth; and emergency obstetric and neonatal care around and after birth. Screening and treatment of maternal syphilis, community based management of neonatal pneumonia, and steroids given during the antenatal period were relatively less cost effective in Sear-D. Scaling up all of the included interventions to 95% coverage would halve neonatal and maternal deaths. CONCLUSION: Preventive interventions at the community level for newborn babies and at the primary care level for mothers and newborn babies are extremely cost effective, but the millennium development goals for maternal and child health will not be achieved without universal access to clinical services as well.",2005-99-01607,16282407,BMJ,Taghreed Adam,2005,331 / 7525,1107,No,16282407,"Taghreed Adam; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries, BMJ, 2005-Nov-12; 331(7525):0959-8138; 1107",DALY,"Botswana, Burundi, Central African Republic, Congo Democratic Republic, Congo, Cte d'Ivoire, Eritrea, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe",Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Pharmaceutical, Screening","Community based management of neonatal pneumonia + community newborn care package + tetanus toxoid + screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria, and screening and treatment of syphilis vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,27,United States,2000,40.58
26146,Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries,"OBJECTIVE: To determine the costs and benefits of interventions for maternal and newborn health to assess the appropriateness of current strategies and guide future plans to attain the millennium development goals. DESIGN: Cost effectiveness analysis. SETTING: Two regions classified by the World Health Organization according to their epidemiological grouping: Afr-E, those countries in sub-Saharan Africa with very high adult and high child mortality, and Sear-D, comprising countries in South East Asia with high adult and high child mortality. DATA SOURCES: Effectiveness data from several sources, including trials, observational studies, and expert opinion. For resource inputs, quantities came from WHO guidelines, literature, and expert opinion, and prices from the WHO choosing interventions that are cost effective database. MAIN OUTCOME MEASURES: Cost per disability adjusted life year (DALY) averted in year 2000 international dollars. RESULTS: The most cost effective mix of interventions was similar in Afr-E and Sear-D. These were the community based newborn care package, followed by antenatal care (tetanus toxoid, screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria and syphilis); skilled attendance at birth, offering first level maternal and neonatal care around childbirth; and emergency obstetric and neonatal care around and after birth. Screening and treatment of maternal syphilis, community based management of neonatal pneumonia, and steroids given during the antenatal period were relatively less cost effective in Sear-D. Scaling up all of the included interventions to 95% coverage would halve neonatal and maternal deaths. CONCLUSION: Preventive interventions at the community level for newborn babies and at the primary care level for mothers and newborn babies are extremely cost effective, but the millennium development goals for maternal and child health will not be achieved without universal access to clinical services as well.",2005-99-01607,16282407,BMJ,Taghreed Adam,2005,331 / 7525,1107,No,16282407,"Taghreed Adam; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries, BMJ, 2005-Nov-12; 331(7525):0959-8138; 1107",DALY,"Botswana, Burundi, Central African Republic, Congo Democratic Republic, Congo, Cte d'Ivoire, Eritrea, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe",Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Pharmaceutical, Screening","Community based management of neonatal pneumonia + community newborn care package + tetanus toxoid + screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria, and screening and treatment of syphilis + skilled maternal care and immediate care of newborn vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,40,United States,2000,60.12
26147,Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries,"OBJECTIVE: To determine the costs and benefits of interventions for maternal and newborn health to assess the appropriateness of current strategies and guide future plans to attain the millennium development goals. DESIGN: Cost effectiveness analysis. SETTING: Two regions classified by the World Health Organization according to their epidemiological grouping: Afr-E, those countries in sub-Saharan Africa with very high adult and high child mortality, and Sear-D, comprising countries in South East Asia with high adult and high child mortality. DATA SOURCES: Effectiveness data from several sources, including trials, observational studies, and expert opinion. For resource inputs, quantities came from WHO guidelines, literature, and expert opinion, and prices from the WHO choosing interventions that are cost effective database. MAIN OUTCOME MEASURES: Cost per disability adjusted life year (DALY) averted in year 2000 international dollars. RESULTS: The most cost effective mix of interventions was similar in Afr-E and Sear-D. These were the community based newborn care package, followed by antenatal care (tetanus toxoid, screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria and syphilis); skilled attendance at birth, offering first level maternal and neonatal care around childbirth; and emergency obstetric and neonatal care around and after birth. Screening and treatment of maternal syphilis, community based management of neonatal pneumonia, and steroids given during the antenatal period were relatively less cost effective in Sear-D. Scaling up all of the included interventions to 95% coverage would halve neonatal and maternal deaths. CONCLUSION: Preventive interventions at the community level for newborn babies and at the primary care level for mothers and newborn babies are extremely cost effective, but the millennium development goals for maternal and child health will not be achieved without universal access to clinical services as well.",2005-99-01607,16282407,BMJ,Taghreed Adam,2005,331 / 7525,1107,No,16282407,"Taghreed Adam; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries, BMJ, 2005-Nov-12; 331(7525):0959-8138; 1107",DALY,"Botswana, Burundi, Central African Republic, Congo Democratic Republic, Congo, Cte d'Ivoire, Eritrea, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe",Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Pharmaceutical, Screening","Community based management of neonatal pneumonia + community newborn care package + tetanus toxoid + screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria, and screening and treatment of syphilis + skilled maternal care and immediate care of newborn +treatment of severe eclampsia vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,42,United States,2000,63.12
26148,Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries,"OBJECTIVE: To determine the costs and benefits of interventions for maternal and newborn health to assess the appropriateness of current strategies and guide future plans to attain the millennium development goals. DESIGN: Cost effectiveness analysis. SETTING: Two regions classified by the World Health Organization according to their epidemiological grouping: Afr-E, those countries in sub-Saharan Africa with very high adult and high child mortality, and Sear-D, comprising countries in South East Asia with high adult and high child mortality. DATA SOURCES: Effectiveness data from several sources, including trials, observational studies, and expert opinion. For resource inputs, quantities came from WHO guidelines, literature, and expert opinion, and prices from the WHO choosing interventions that are cost effective database. MAIN OUTCOME MEASURES: Cost per disability adjusted life year (DALY) averted in year 2000 international dollars. RESULTS: The most cost effective mix of interventions was similar in Afr-E and Sear-D. These were the community based newborn care package, followed by antenatal care (tetanus toxoid, screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria and syphilis); skilled attendance at birth, offering first level maternal and neonatal care around childbirth; and emergency obstetric and neonatal care around and after birth. Screening and treatment of maternal syphilis, community based management of neonatal pneumonia, and steroids given during the antenatal period were relatively less cost effective in Sear-D. Scaling up all of the included interventions to 95% coverage would halve neonatal and maternal deaths. CONCLUSION: Preventive interventions at the community level for newborn babies and at the primary care level for mothers and newborn babies are extremely cost effective, but the millennium development goals for maternal and child health will not be achieved without universal access to clinical services as well.",2005-99-01607,16282407,BMJ,Taghreed Adam,2005,331 / 7525,1107,No,16282407,"Taghreed Adam; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries, BMJ, 2005-Nov-12; 331(7525):0959-8138; 1107",DALY,"Botswana, Burundi, Central African Republic, Congo Democratic Republic, Congo, Cte d'Ivoire, Eritrea, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe",Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Pharmaceutical, Screening","Community based management of neonatal pneumonia + community newborn care package + tetanus toxoid + screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria, and screening and treatment of syphilis + skilled maternal care and immediate care of newborn +treatment of severe eclampsia+emergency neonatal care vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,61,United States,2000,91.68
26149,Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries,"OBJECTIVE: To determine the costs and benefits of interventions for maternal and newborn health to assess the appropriateness of current strategies and guide future plans to attain the millennium development goals. DESIGN: Cost effectiveness analysis. SETTING: Two regions classified by the World Health Organization according to their epidemiological grouping: Afr-E, those countries in sub-Saharan Africa with very high adult and high child mortality, and Sear-D, comprising countries in South East Asia with high adult and high child mortality. DATA SOURCES: Effectiveness data from several sources, including trials, observational studies, and expert opinion. For resource inputs, quantities came from WHO guidelines, literature, and expert opinion, and prices from the WHO choosing interventions that are cost effective database. MAIN OUTCOME MEASURES: Cost per disability adjusted life year (DALY) averted in year 2000 international dollars. RESULTS: The most cost effective mix of interventions was similar in Afr-E and Sear-D. These were the community based newborn care package, followed by antenatal care (tetanus toxoid, screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria and syphilis); skilled attendance at birth, offering first level maternal and neonatal care around childbirth; and emergency obstetric and neonatal care around and after birth. Screening and treatment of maternal syphilis, community based management of neonatal pneumonia, and steroids given during the antenatal period were relatively less cost effective in Sear-D. Scaling up all of the included interventions to 95% coverage would halve neonatal and maternal deaths. CONCLUSION: Preventive interventions at the community level for newborn babies and at the primary care level for mothers and newborn babies are extremely cost effective, but the millennium development goals for maternal and child health will not be achieved without universal access to clinical services as well.",2005-99-01607,16282407,BMJ,Taghreed Adam,2005,331 / 7525,1107,No,16282407,"Taghreed Adam; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries, BMJ, 2005-Nov-12; 331(7525):0959-8138; 1107",DALY,"Botswana, Burundi, Central African Republic, Congo Democratic Republic, Congo, Cte d'Ivoire, Eritrea, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe",Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Pharmaceutical, Screening","Community based management of neonatal pneumonia + community newborn care package + tetanus toxoid + screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria, and screening and treatment of syphilis + skilled maternal care and immediate care of newborn +treatment of severe eclampsia+emergency neonatal care+management of obstructed labour, breech presentation and fetal distress vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,73,United States,2000,109.72
26150,Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries,"OBJECTIVE: To determine the costs and benefits of interventions for maternal and newborn health to assess the appropriateness of current strategies and guide future plans to attain the millennium development goals. DESIGN: Cost effectiveness analysis. SETTING: Two regions classified by the World Health Organization according to their epidemiological grouping: Afr-E, those countries in sub-Saharan Africa with very high adult and high child mortality, and Sear-D, comprising countries in South East Asia with high adult and high child mortality. DATA SOURCES: Effectiveness data from several sources, including trials, observational studies, and expert opinion. For resource inputs, quantities came from WHO guidelines, literature, and expert opinion, and prices from the WHO choosing interventions that are cost effective database. MAIN OUTCOME MEASURES: Cost per disability adjusted life year (DALY) averted in year 2000 international dollars. RESULTS: The most cost effective mix of interventions was similar in Afr-E and Sear-D. These were the community based newborn care package, followed by antenatal care (tetanus toxoid, screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria and syphilis); skilled attendance at birth, offering first level maternal and neonatal care around childbirth; and emergency obstetric and neonatal care around and after birth. Screening and treatment of maternal syphilis, community based management of neonatal pneumonia, and steroids given during the antenatal period were relatively less cost effective in Sear-D. Scaling up all of the included interventions to 95% coverage would halve neonatal and maternal deaths. CONCLUSION: Preventive interventions at the community level for newborn babies and at the primary care level for mothers and newborn babies are extremely cost effective, but the millennium development goals for maternal and child health will not be achieved without universal access to clinical services as well.",2005-99-01607,16282407,BMJ,Taghreed Adam,2005,331 / 7525,1107,No,16282407,"Taghreed Adam; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries, BMJ, 2005-Nov-12; 331(7525):0959-8138; 1107",DALY,"Botswana, Burundi, Central African Republic, Congo Democratic Republic, Congo, Cte d'Ivoire, Eritrea, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe",Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Pharmaceutical, Screening","Community based management of neonatal pneumonia + community newborn care package + tetanus toxoid + screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria, and screening and treatment of syphilis + skilled maternal care and immediate care of newborn +treatment of severe eclampsia+emergency neonatal care+management of obstructed labour, breech presentation and fetal distress+steroids for preterm births vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,117,United States,2000,175.85
26151,Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries,"OBJECTIVE: To determine the costs and benefits of interventions for maternal and newborn health to assess the appropriateness of current strategies and guide future plans to attain the millennium development goals. DESIGN: Cost effectiveness analysis. SETTING: Two regions classified by the World Health Organization according to their epidemiological grouping: Afr-E, those countries in sub-Saharan Africa with very high adult and high child mortality, and Sear-D, comprising countries in South East Asia with high adult and high child mortality. DATA SOURCES: Effectiveness data from several sources, including trials, observational studies, and expert opinion. For resource inputs, quantities came from WHO guidelines, literature, and expert opinion, and prices from the WHO choosing interventions that are cost effective database. MAIN OUTCOME MEASURES: Cost per disability adjusted life year (DALY) averted in year 2000 international dollars. RESULTS: The most cost effective mix of interventions was similar in Afr-E and Sear-D. These were the community based newborn care package, followed by antenatal care (tetanus toxoid, screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria and syphilis); skilled attendance at birth, offering first level maternal and neonatal care around childbirth; and emergency obstetric and neonatal care around and after birth. Screening and treatment of maternal syphilis, community based management of neonatal pneumonia, and steroids given during the antenatal period were relatively less cost effective in Sear-D. Scaling up all of the included interventions to 95% coverage would halve neonatal and maternal deaths. CONCLUSION: Preventive interventions at the community level for newborn babies and at the primary care level for mothers and newborn babies are extremely cost effective, but the millennium development goals for maternal and child health will not be achieved without universal access to clinical services as well.",2005-99-01607,16282407,BMJ,Taghreed Adam,2005,331 / 7525,1107,No,16282407,"Taghreed Adam; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries, BMJ, 2005-Nov-12; 331(7525):0959-8138; 1107",DALY,"Botswana, Burundi, Central African Republic, Congo Democratic Republic, Congo, Cte d'Ivoire, Eritrea, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe",Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Pharmaceutical, Screening","Community based management of neonatal pneumonia + community newborn care package + tetanus toxoid + screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria, and screening and treatment of syphilis + skilled maternal care and immediate care of newborn +treatment of severe eclampsia+emergency neonatal care+management of obstructed labour, breech presentation and fetal distress+steroids for preterm births+management of maternal sepsis vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,125,United States,2000,187.87
26152,Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries,"OBJECTIVE: To determine the costs and benefits of interventions for maternal and newborn health to assess the appropriateness of current strategies and guide future plans to attain the millennium development goals. DESIGN: Cost effectiveness analysis. SETTING: Two regions classified by the World Health Organization according to their epidemiological grouping: Afr-E, those countries in sub-Saharan Africa with very high adult and high child mortality, and Sear-D, comprising countries in South East Asia with high adult and high child mortality. DATA SOURCES: Effectiveness data from several sources, including trials, observational studies, and expert opinion. For resource inputs, quantities came from WHO guidelines, literature, and expert opinion, and prices from the WHO choosing interventions that are cost effective database. MAIN OUTCOME MEASURES: Cost per disability adjusted life year (DALY) averted in year 2000 international dollars. RESULTS: The most cost effective mix of interventions was similar in Afr-E and Sear-D. These were the community based newborn care package, followed by antenatal care (tetanus toxoid, screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria and syphilis); skilled attendance at birth, offering first level maternal and neonatal care around childbirth; and emergency obstetric and neonatal care around and after birth. Screening and treatment of maternal syphilis, community based management of neonatal pneumonia, and steroids given during the antenatal period were relatively less cost effective in Sear-D. Scaling up all of the included interventions to 95% coverage would halve neonatal and maternal deaths. CONCLUSION: Preventive interventions at the community level for newborn babies and at the primary care level for mothers and newborn babies are extremely cost effective, but the millennium development goals for maternal and child health will not be achieved without universal access to clinical services as well.",2005-99-01607,16282407,BMJ,Taghreed Adam,2005,331 / 7525,1107,No,16282407,"Taghreed Adam; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries, BMJ, 2005-Nov-12; 331(7525):0959-8138; 1107",DALY,"Botswana, Burundi, Central African Republic, Congo Democratic Republic, Congo, Cte d'Ivoire, Eritrea, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe",Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Pharmaceutical, Screening","Community based management of neonatal pneumonia + community newborn care package + tetanus toxoid + screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria, and screening and treatment of syphilis + skilled maternal care and immediate care of newborn +treatment of severe eclampsia+emergency neonatal care+management of obstructed labour, breech presentation and fetal distress+steroids for preterm births+management of maternal sepsis+antibiotics for preterm premature rupture of membranes vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,178,United States,2000,267.53
26153,Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries,"OBJECTIVE: To determine the costs and benefits of interventions for maternal and newborn health to assess the appropriateness of current strategies and guide future plans to attain the millennium development goals. DESIGN: Cost effectiveness analysis. SETTING: Two regions classified by the World Health Organization according to their epidemiological grouping: Afr-E, those countries in sub-Saharan Africa with very high adult and high child mortality, and Sear-D, comprising countries in South East Asia with high adult and high child mortality. DATA SOURCES: Effectiveness data from several sources, including trials, observational studies, and expert opinion. For resource inputs, quantities came from WHO guidelines, literature, and expert opinion, and prices from the WHO choosing interventions that are cost effective database. MAIN OUTCOME MEASURES: Cost per disability adjusted life year (DALY) averted in year 2000 international dollars. RESULTS: The most cost effective mix of interventions was similar in Afr-E and Sear-D. These were the community based newborn care package, followed by antenatal care (tetanus toxoid, screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria and syphilis); skilled attendance at birth, offering first level maternal and neonatal care around childbirth; and emergency obstetric and neonatal care around and after birth. Screening and treatment of maternal syphilis, community based management of neonatal pneumonia, and steroids given during the antenatal period were relatively less cost effective in Sear-D. Scaling up all of the included interventions to 95% coverage would halve neonatal and maternal deaths. CONCLUSION: Preventive interventions at the community level for newborn babies and at the primary care level for mothers and newborn babies are extremely cost effective, but the millennium development goals for maternal and child health will not be achieved without universal access to clinical services as well.",2005-99-01607,16282407,BMJ,Taghreed Adam,2005,331 / 7525,1107,No,16282407,"Taghreed Adam; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries, BMJ, 2005-Nov-12; 331(7525):0959-8138; 1107",DALY,"Botswana, Burundi, Central African Republic, Congo Democratic Republic, Congo, Cte d'Ivoire, Eritrea, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe",Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Pharmaceutical, Screening","Community cased management of neonatal pneumonia+ community newborn care package + tetanus toxoid + screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria, and screening and treatment of syphilis+ skilled maternal care and immediate care of newborn +treatment of severe eclampsia+emergency neonatal care+management of obstructed labour, breech presentation and fetal distress+steroids for preterm births+management of maternal sepsis+antibiotics for preterm premature rupture of membranes+referral for postpartum hemorrhage vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,223,United States,2000,335.16
26154,Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries,"OBJECTIVE: To determine the costs and benefits of interventions for maternal and newborn health to assess the appropriateness of current strategies and guide future plans to attain the millennium development goals. DESIGN: Cost effectiveness analysis. SETTING: Two regions classified by the World Health Organization according to their epidemiological grouping: Afr-E, those countries in sub-Saharan Africa with very high adult and high child mortality, and Sear-D, comprising countries in South East Asia with high adult and high child mortality. DATA SOURCES: Effectiveness data from several sources, including trials, observational studies, and expert opinion. For resource inputs, quantities came from WHO guidelines, literature, and expert opinion, and prices from the WHO choosing interventions that are cost effective database. MAIN OUTCOME MEASURES: Cost per disability adjusted life year (DALY) averted in year 2000 international dollars. RESULTS: The most cost effective mix of interventions was similar in Afr-E and Sear-D. These were the community based newborn care package, followed by antenatal care (tetanus toxoid, screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria and syphilis); skilled attendance at birth, offering first level maternal and neonatal care around childbirth; and emergency obstetric and neonatal care around and after birth. Screening and treatment of maternal syphilis, community based management of neonatal pneumonia, and steroids given during the antenatal period were relatively less cost effective in Sear-D. Scaling up all of the included interventions to 95% coverage would halve neonatal and maternal deaths. CONCLUSION: Preventive interventions at the community level for newborn babies and at the primary care level for mothers and newborn babies are extremely cost effective, but the millennium development goals for maternal and child health will not be achieved without universal access to clinical services as well.",2005-99-01607,16282407,BMJ,Taghreed Adam,2005,331 / 7525,1107,No,16282407,"Taghreed Adam; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries, BMJ, 2005-Nov-12; 331(7525):0959-8138; 1107",DALY,"Bangladesh, Bhutan, India, North Korea, Maldives, Myanmar, Nepal, Timor-Leste",Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Pharmaceutical, Screening",Support for breast feeding mothers vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,6,United States,2000,9.02
26155,Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries,"OBJECTIVE: To determine the costs and benefits of interventions for maternal and newborn health to assess the appropriateness of current strategies and guide future plans to attain the millennium development goals. DESIGN: Cost effectiveness analysis. SETTING: Two regions classified by the World Health Organization according to their epidemiological grouping: Afr-E, those countries in sub-Saharan Africa with very high adult and high child mortality, and Sear-D, comprising countries in South East Asia with high adult and high child mortality. DATA SOURCES: Effectiveness data from several sources, including trials, observational studies, and expert opinion. For resource inputs, quantities came from WHO guidelines, literature, and expert opinion, and prices from the WHO choosing interventions that are cost effective database. MAIN OUTCOME MEASURES: Cost per disability adjusted life year (DALY) averted in year 2000 international dollars. RESULTS: The most cost effective mix of interventions was similar in Afr-E and Sear-D. These were the community based newborn care package, followed by antenatal care (tetanus toxoid, screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria and syphilis); skilled attendance at birth, offering first level maternal and neonatal care around childbirth; and emergency obstetric and neonatal care around and after birth. Screening and treatment of maternal syphilis, community based management of neonatal pneumonia, and steroids given during the antenatal period were relatively less cost effective in Sear-D. Scaling up all of the included interventions to 95% coverage would halve neonatal and maternal deaths. CONCLUSION: Preventive interventions at the community level for newborn babies and at the primary care level for mothers and newborn babies are extremely cost effective, but the millennium development goals for maternal and child health will not be achieved without universal access to clinical services as well.",2005-99-01607,16282407,BMJ,Taghreed Adam,2005,331 / 7525,1107,No,16282407,"Taghreed Adam; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries, BMJ, 2005-Nov-12; 331(7525):0959-8138; 1107",DALY,"Bangladesh, Bhutan, India, North Korea, Maldives, Myanmar, Nepal, Timor-Leste",Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Pharmaceutical, Screening",Support for breast feeding mothers + tetanus toxoid vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,8,United States,2000,12.02
26156,Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries,"OBJECTIVE: To determine the costs and benefits of interventions for maternal and newborn health to assess the appropriateness of current strategies and guide future plans to attain the millennium development goals. DESIGN: Cost effectiveness analysis. SETTING: Two regions classified by the World Health Organization according to their epidemiological grouping: Afr-E, those countries in sub-Saharan Africa with very high adult and high child mortality, and Sear-D, comprising countries in South East Asia with high adult and high child mortality. DATA SOURCES: Effectiveness data from several sources, including trials, observational studies, and expert opinion. For resource inputs, quantities came from WHO guidelines, literature, and expert opinion, and prices from the WHO choosing interventions that are cost effective database. MAIN OUTCOME MEASURES: Cost per disability adjusted life year (DALY) averted in year 2000 international dollars. RESULTS: The most cost effective mix of interventions was similar in Afr-E and Sear-D. These were the community based newborn care package, followed by antenatal care (tetanus toxoid, screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria and syphilis); skilled attendance at birth, offering first level maternal and neonatal care around childbirth; and emergency obstetric and neonatal care around and after birth. Screening and treatment of maternal syphilis, community based management of neonatal pneumonia, and steroids given during the antenatal period were relatively less cost effective in Sear-D. Scaling up all of the included interventions to 95% coverage would halve neonatal and maternal deaths. CONCLUSION: Preventive interventions at the community level for newborn babies and at the primary care level for mothers and newborn babies are extremely cost effective, but the millennium development goals for maternal and child health will not be achieved without universal access to clinical services as well.",2005-99-01607,16282407,BMJ,Taghreed Adam,2005,331 / 7525,1107,No,16282407,"Taghreed Adam; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries, BMJ, 2005-Nov-12; 331(7525):0959-8138; 1107",DALY,"Bangladesh, Bhutan, India, North Korea, Maldives, Myanmar, Nepal, Timor-Leste",Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Pharmaceutical, Screening",Community Care of newborn + tetanus toxoid vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,20,United States,2000,30.06
26157,Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries,"OBJECTIVE: To determine the costs and benefits of interventions for maternal and newborn health to assess the appropriateness of current strategies and guide future plans to attain the millennium development goals. DESIGN: Cost effectiveness analysis. SETTING: Two regions classified by the World Health Organization according to their epidemiological grouping: Afr-E, those countries in sub-Saharan Africa with very high adult and high child mortality, and Sear-D, comprising countries in South East Asia with high adult and high child mortality. DATA SOURCES: Effectiveness data from several sources, including trials, observational studies, and expert opinion. For resource inputs, quantities came from WHO guidelines, literature, and expert opinion, and prices from the WHO choosing interventions that are cost effective database. MAIN OUTCOME MEASURES: Cost per disability adjusted life year (DALY) averted in year 2000 international dollars. RESULTS: The most cost effective mix of interventions was similar in Afr-E and Sear-D. These were the community based newborn care package, followed by antenatal care (tetanus toxoid, screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria and syphilis); skilled attendance at birth, offering first level maternal and neonatal care around childbirth; and emergency obstetric and neonatal care around and after birth. Screening and treatment of maternal syphilis, community based management of neonatal pneumonia, and steroids given during the antenatal period were relatively less cost effective in Sear-D. Scaling up all of the included interventions to 95% coverage would halve neonatal and maternal deaths. CONCLUSION: Preventive interventions at the community level for newborn babies and at the primary care level for mothers and newborn babies are extremely cost effective, but the millennium development goals for maternal and child health will not be achieved without universal access to clinical services as well.",2005-99-01607,16282407,BMJ,Taghreed Adam,2005,331 / 7525,1107,No,16282407,"Taghreed Adam; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries, BMJ, 2005-Nov-12; 331(7525):0959-8138; 1107",DALY,"Bangladesh, Bhutan, India, North Korea, Maldives, Myanmar, Nepal, Timor-Leste",Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Pharmaceutical, Screening",Community Care of newborn + tetanus toxoid + normal delivery by skilled attendant + active management and initial treatment of postpartum hemorrhage vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,88,United States,2000,132.26
26158,Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries,"OBJECTIVE: To determine the costs and benefits of interventions for maternal and newborn health to assess the appropriateness of current strategies and guide future plans to attain the millennium development goals. DESIGN: Cost effectiveness analysis. SETTING: Two regions classified by the World Health Organization according to their epidemiological grouping: Afr-E, those countries in sub-Saharan Africa with very high adult and high child mortality, and Sear-D, comprising countries in South East Asia with high adult and high child mortality. DATA SOURCES: Effectiveness data from several sources, including trials, observational studies, and expert opinion. For resource inputs, quantities came from WHO guidelines, literature, and expert opinion, and prices from the WHO choosing interventions that are cost effective database. MAIN OUTCOME MEASURES: Cost per disability adjusted life year (DALY) averted in year 2000 international dollars. RESULTS: The most cost effective mix of interventions was similar in Afr-E and Sear-D. These were the community based newborn care package, followed by antenatal care (tetanus toxoid, screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria and syphilis); skilled attendance at birth, offering first level maternal and neonatal care around childbirth; and emergency obstetric and neonatal care around and after birth. Screening and treatment of maternal syphilis, community based management of neonatal pneumonia, and steroids given during the antenatal period were relatively less cost effective in Sear-D. Scaling up all of the included interventions to 95% coverage would halve neonatal and maternal deaths. CONCLUSION: Preventive interventions at the community level for newborn babies and at the primary care level for mothers and newborn babies are extremely cost effective, but the millennium development goals for maternal and child health will not be achieved without universal access to clinical services as well.",2005-99-01607,16282407,BMJ,Taghreed Adam,2005,331 / 7525,1107,No,16282407,"Taghreed Adam; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries, BMJ, 2005-Nov-12; 331(7525):0959-8138; 1107",DALY,"Bangladesh, Bhutan, India, North Korea, Maldives, Myanmar, Nepal, Timor-Leste",Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Pharmaceutical, Screening",Community Care of newborn + tetanus toxoid + normal delivery by skilled attendant + active management and initial treatment of postpartum haemorrhage+screening for pre-eclampsia and screening for and treatment of asymptomatic bacteriuria vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,123,United States,2000,184.87
26159,Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries,"OBJECTIVE: To determine the costs and benefits of interventions for maternal and newborn health to assess the appropriateness of current strategies and guide future plans to attain the millennium development goals. DESIGN: Cost effectiveness analysis. SETTING: Two regions classified by the World Health Organization according to their epidemiological grouping: Afr-E, those countries in sub-Saharan Africa with very high adult and high child mortality, and Sear-D, comprising countries in South East Asia with high adult and high child mortality. DATA SOURCES: Effectiveness data from several sources, including trials, observational studies, and expert opinion. For resource inputs, quantities came from WHO guidelines, literature, and expert opinion, and prices from the WHO choosing interventions that are cost effective database. MAIN OUTCOME MEASURES: Cost per disability adjusted life year (DALY) averted in year 2000 international dollars. RESULTS: The most cost effective mix of interventions was similar in Afr-E and Sear-D. These were the community based newborn care package, followed by antenatal care (tetanus toxoid, screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria and syphilis); skilled attendance at birth, offering first level maternal and neonatal care around childbirth; and emergency obstetric and neonatal care around and after birth. Screening and treatment of maternal syphilis, community based management of neonatal pneumonia, and steroids given during the antenatal period were relatively less cost effective in Sear-D. Scaling up all of the included interventions to 95% coverage would halve neonatal and maternal deaths. CONCLUSION: Preventive interventions at the community level for newborn babies and at the primary care level for mothers and newborn babies are extremely cost effective, but the millennium development goals for maternal and child health will not be achieved without universal access to clinical services as well.",2005-99-01607,16282407,BMJ,Taghreed Adam,2005,331 / 7525,1107,No,16282407,"Taghreed Adam; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries, BMJ, 2005-Nov-12; 331(7525):0959-8138; 1107",DALY,"Bangladesh, Bhutan, India, North Korea, Maldives, Myanmar, Nepal, Timor-Leste",Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Pharmaceutical, Screening",Community Care of newborn + tetanus toxoid + normal delivery by skilled attendant + active management and initial treatment of postpartum haemorrhage+screening for pre-eclampsia and screening for and treatment of asymptomatic bacteriuria+community based management of neonatal pneumonia vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,144,United States,2000,216.43
26160,Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries,"OBJECTIVE: To determine the costs and benefits of interventions for maternal and newborn health to assess the appropriateness of current strategies and guide future plans to attain the millennium development goals. DESIGN: Cost effectiveness analysis. SETTING: Two regions classified by the World Health Organization according to their epidemiological grouping: Afr-E, those countries in sub-Saharan Africa with very high adult and high child mortality, and Sear-D, comprising countries in South East Asia with high adult and high child mortality. DATA SOURCES: Effectiveness data from several sources, including trials, observational studies, and expert opinion. For resource inputs, quantities came from WHO guidelines, literature, and expert opinion, and prices from the WHO choosing interventions that are cost effective database. MAIN OUTCOME MEASURES: Cost per disability adjusted life year (DALY) averted in year 2000 international dollars. RESULTS: The most cost effective mix of interventions was similar in Afr-E and Sear-D. These were the community based newborn care package, followed by antenatal care (tetanus toxoid, screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria and syphilis); skilled attendance at birth, offering first level maternal and neonatal care around childbirth; and emergency obstetric and neonatal care around and after birth. Screening and treatment of maternal syphilis, community based management of neonatal pneumonia, and steroids given during the antenatal period were relatively less cost effective in Sear-D. Scaling up all of the included interventions to 95% coverage would halve neonatal and maternal deaths. CONCLUSION: Preventive interventions at the community level for newborn babies and at the primary care level for mothers and newborn babies are extremely cost effective, but the millennium development goals for maternal and child health will not be achieved without universal access to clinical services as well.",2005-99-01607,16282407,BMJ,Taghreed Adam,2005,331 / 7525,1107,No,16282407,"Taghreed Adam; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries, BMJ, 2005-Nov-12; 331(7525):0959-8138; 1107",DALY,"Bangladesh, Bhutan, India, North Korea, Maldives, Myanmar, Nepal, Timor-Leste",Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Pharmaceutical, Screening",Community Care of newborn + tetanus toxoid + normal delivery by skilled attendant + active management and initial treatment of postpartum haemorrhage+screening for pre-eclampsia and screening for and treatment of asymptomatic bacteriuria+community based management of neonatal pneumonia+neonatal resuscitation+treatment of severe pre-eclampsia or eclampsia vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,218,United States,2000,327.65
26161,Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries,"OBJECTIVE: To determine the costs and benefits of interventions for maternal and newborn health to assess the appropriateness of current strategies and guide future plans to attain the millennium development goals. DESIGN: Cost effectiveness analysis. SETTING: Two regions classified by the World Health Organization according to their epidemiological grouping: Afr-E, those countries in sub-Saharan Africa with very high adult and high child mortality, and Sear-D, comprising countries in South East Asia with high adult and high child mortality. DATA SOURCES: Effectiveness data from several sources, including trials, observational studies, and expert opinion. For resource inputs, quantities came from WHO guidelines, literature, and expert opinion, and prices from the WHO choosing interventions that are cost effective database. MAIN OUTCOME MEASURES: Cost per disability adjusted life year (DALY) averted in year 2000 international dollars. RESULTS: The most cost effective mix of interventions was similar in Afr-E and Sear-D. These were the community based newborn care package, followed by antenatal care (tetanus toxoid, screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria and syphilis); skilled attendance at birth, offering first level maternal and neonatal care around childbirth; and emergency obstetric and neonatal care around and after birth. Screening and treatment of maternal syphilis, community based management of neonatal pneumonia, and steroids given during the antenatal period were relatively less cost effective in Sear-D. Scaling up all of the included interventions to 95% coverage would halve neonatal and maternal deaths. CONCLUSION: Preventive interventions at the community level for newborn babies and at the primary care level for mothers and newborn babies are extremely cost effective, but the millennium development goals for maternal and child health will not be achieved without universal access to clinical services as well.",2005-99-01607,16282407,BMJ,Taghreed Adam,2005,331 / 7525,1107,No,16282407,"Taghreed Adam; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries, BMJ, 2005-Nov-12; 331(7525):0959-8138; 1107",DALY,"Bangladesh, Bhutan, India, North Korea, Maldives, Myanmar, Nepal, Timor-Leste",Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Pharmaceutical, Screening",Community Care of newborn + tetanus toxoid + normal delivery by skilled attendant + active management and initial treatment of postpartum haemorrhage+screening for pre-eclampsia and screening for and treatment of asymptomatic bacteriuria+community based management of neonatal pneumonia+neonatal resuscitation+treatment of severe pre-eclampsia or eclampsia+referral of postpartum hemorrhage vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,261,United States,2000,392.27
26162,Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries,"OBJECTIVE: To determine the costs and benefits of interventions for maternal and newborn health to assess the appropriateness of current strategies and guide future plans to attain the millennium development goals. DESIGN: Cost effectiveness analysis. SETTING: Two regions classified by the World Health Organization according to their epidemiological grouping: Afr-E, those countries in sub-Saharan Africa with very high adult and high child mortality, and Sear-D, comprising countries in South East Asia with high adult and high child mortality. DATA SOURCES: Effectiveness data from several sources, including trials, observational studies, and expert opinion. For resource inputs, quantities came from WHO guidelines, literature, and expert opinion, and prices from the WHO choosing interventions that are cost effective database. MAIN OUTCOME MEASURES: Cost per disability adjusted life year (DALY) averted in year 2000 international dollars. RESULTS: The most cost effective mix of interventions was similar in Afr-E and Sear-D. These were the community based newborn care package, followed by antenatal care (tetanus toxoid, screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria and syphilis); skilled attendance at birth, offering first level maternal and neonatal care around childbirth; and emergency obstetric and neonatal care around and after birth. Screening and treatment of maternal syphilis, community based management of neonatal pneumonia, and steroids given during the antenatal period were relatively less cost effective in Sear-D. Scaling up all of the included interventions to 95% coverage would halve neonatal and maternal deaths. CONCLUSION: Preventive interventions at the community level for newborn babies and at the primary care level for mothers and newborn babies are extremely cost effective, but the millennium development goals for maternal and child health will not be achieved without universal access to clinical services as well.",2005-99-01607,16282407,BMJ,Taghreed Adam,2005,331 / 7525,1107,No,16282407,"Taghreed Adam; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries, BMJ, 2005-Nov-12; 331(7525):0959-8138; 1107",DALY,"Bangladesh, Bhutan, India, North Korea, Maldives, Myanmar, Nepal, Timor-Leste",Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Pharmaceutical, Screening",Community Care of newborn + tetanus toxoid + normal delivery by skilled attendant + active management and initial treatment of postpartum haemorrhage+screening for pre-eclampsia and screening for and treatment of asymptomatic bacteriuria+community based management of neonatal pneumonia+neonatal resuscitation+treatment of severe pre-eclampsia or eclampsia+referral of postpartum haemorrhage+management of maternal sepsis vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,290,United States,2000,435.86
26163,Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries,"OBJECTIVE: To determine the costs and benefits of interventions for maternal and newborn health to assess the appropriateness of current strategies and guide future plans to attain the millennium development goals. DESIGN: Cost effectiveness analysis. SETTING: Two regions classified by the World Health Organization according to their epidemiological grouping: Afr-E, those countries in sub-Saharan Africa with very high adult and high child mortality, and Sear-D, comprising countries in South East Asia with high adult and high child mortality. DATA SOURCES: Effectiveness data from several sources, including trials, observational studies, and expert opinion. For resource inputs, quantities came from WHO guidelines, literature, and expert opinion, and prices from the WHO choosing interventions that are cost effective database. MAIN OUTCOME MEASURES: Cost per disability adjusted life year (DALY) averted in year 2000 international dollars. RESULTS: The most cost effective mix of interventions was similar in Afr-E and Sear-D. These were the community based newborn care package, followed by antenatal care (tetanus toxoid, screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria and syphilis); skilled attendance at birth, offering first level maternal and neonatal care around childbirth; and emergency obstetric and neonatal care around and after birth. Screening and treatment of maternal syphilis, community based management of neonatal pneumonia, and steroids given during the antenatal period were relatively less cost effective in Sear-D. Scaling up all of the included interventions to 95% coverage would halve neonatal and maternal deaths. CONCLUSION: Preventive interventions at the community level for newborn babies and at the primary care level for mothers and newborn babies are extremely cost effective, but the millennium development goals for maternal and child health will not be achieved without universal access to clinical services as well.",2005-99-01607,16282407,BMJ,Taghreed Adam,2005,331 / 7525,1107,No,16282407,"Taghreed Adam; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries, BMJ, 2005-Nov-12; 331(7525):0959-8138; 1107",DALY,"Bangladesh, Bhutan, India, North Korea, Maldives, Myanmar, Nepal, Timor-Leste",Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Pharmaceutical, Screening",Community Care of newborn + tetanus toxoid + normal delivery by skilled attendant + active management and initial treatment of postpartum haemorrhage+screening for pre-eclampsia and screening for and treatment of asymptomatic bacteriuria+community based management of neonatal pneumonia+neonatal resuscitation+treatment of severe pre-eclampsia or eclampsia+referral of postpartum haemorrhage+management of maternal sepsis+emergency neonatal care vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,614,United States,2000,922.82
26164,Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries,"OBJECTIVE: To determine the costs and benefits of interventions for maternal and newborn health to assess the appropriateness of current strategies and guide future plans to attain the millennium development goals. DESIGN: Cost effectiveness analysis. SETTING: Two regions classified by the World Health Organization according to their epidemiological grouping: Afr-E, those countries in sub-Saharan Africa with very high adult and high child mortality, and Sear-D, comprising countries in South East Asia with high adult and high child mortality. DATA SOURCES: Effectiveness data from several sources, including trials, observational studies, and expert opinion. For resource inputs, quantities came from WHO guidelines, literature, and expert opinion, and prices from the WHO choosing interventions that are cost effective database. MAIN OUTCOME MEASURES: Cost per disability adjusted life year (DALY) averted in year 2000 international dollars. RESULTS: The most cost effective mix of interventions was similar in Afr-E and Sear-D. These were the community based newborn care package, followed by antenatal care (tetanus toxoid, screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria and syphilis); skilled attendance at birth, offering first level maternal and neonatal care around childbirth; and emergency obstetric and neonatal care around and after birth. Screening and treatment of maternal syphilis, community based management of neonatal pneumonia, and steroids given during the antenatal period were relatively less cost effective in Sear-D. Scaling up all of the included interventions to 95% coverage would halve neonatal and maternal deaths. CONCLUSION: Preventive interventions at the community level for newborn babies and at the primary care level for mothers and newborn babies are extremely cost effective, but the millennium development goals for maternal and child health will not be achieved without universal access to clinical services as well.",2005-99-01607,16282407,BMJ,Taghreed Adam,2005,331 / 7525,1107,No,16282407,"Taghreed Adam; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries, BMJ, 2005-Nov-12; 331(7525):0959-8138; 1107",DALY,"Bangladesh, Bhutan, India, North Korea, Maldives, Myanmar, Nepal, Timor-Leste",Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Pharmaceutical, Screening",Community Care of newborn + tetanus toxoid + normal delivery by skilled attendant + active management and initial treatment of postpartum haemorrhage+screening for pre-eclampsia and screening for and treatment of asymptomatic bacteriuria+community based management of neonatal pneumonia+neonatal resuscitation+treatment of severe pre-eclampsia or eclampsia+referral of postpartum haemorrhage+management of maternal sepsis+emergency neonatal care+screening and treatment of syphilis vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,699,United States,2000,1050.57
26165,Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries,"OBJECTIVE: To determine the costs and benefits of interventions for maternal and newborn health to assess the appropriateness of current strategies and guide future plans to attain the millennium development goals. DESIGN: Cost effectiveness analysis. SETTING: Two regions classified by the World Health Organization according to their epidemiological grouping: Afr-E, those countries in sub-Saharan Africa with very high adult and high child mortality, and Sear-D, comprising countries in South East Asia with high adult and high child mortality. DATA SOURCES: Effectiveness data from several sources, including trials, observational studies, and expert opinion. For resource inputs, quantities came from WHO guidelines, literature, and expert opinion, and prices from the WHO choosing interventions that are cost effective database. MAIN OUTCOME MEASURES: Cost per disability adjusted life year (DALY) averted in year 2000 international dollars. RESULTS: The most cost effective mix of interventions was similar in Afr-E and Sear-D. These were the community based newborn care package, followed by antenatal care (tetanus toxoid, screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria and syphilis); skilled attendance at birth, offering first level maternal and neonatal care around childbirth; and emergency obstetric and neonatal care around and after birth. Screening and treatment of maternal syphilis, community based management of neonatal pneumonia, and steroids given during the antenatal period were relatively less cost effective in Sear-D. Scaling up all of the included interventions to 95% coverage would halve neonatal and maternal deaths. CONCLUSION: Preventive interventions at the community level for newborn babies and at the primary care level for mothers and newborn babies are extremely cost effective, but the millennium development goals for maternal and child health will not be achieved without universal access to clinical services as well.",2005-99-01607,16282407,BMJ,Taghreed Adam,2005,331 / 7525,1107,No,16282407,"Taghreed Adam; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries, BMJ, 2005-Nov-12; 331(7525):0959-8138; 1107",DALY,"Bangladesh, Bhutan, India, North Korea, Maldives, Myanmar, Nepal, Timor-Leste",Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Pharmaceutical, Screening","Community Care of newborn + tetanus toxoid + normal delivery by skilled attendant + active management and initial treatment of postpartum haemorrhage+screening for pre-eclampsia and screening for and treatment of asymptomatic bacteriuria+community based management of neonatal pneumonia+neonatal resuscitation+treatment of severe pre-eclampsia or eclampsia+referral of postpartum haemorrhage+management of maternal sepsis+emergency neonatal care+screening and treatment of syphilis+management of obstructed labour, breech presentation, and fetal distress vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,2638,United States,2000,3964.83
26166,Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries,"OBJECTIVE: To determine the costs and benefits of interventions for maternal and newborn health to assess the appropriateness of current strategies and guide future plans to attain the millennium development goals. DESIGN: Cost effectiveness analysis. SETTING: Two regions classified by the World Health Organization according to their epidemiological grouping: Afr-E, those countries in sub-Saharan Africa with very high adult and high child mortality, and Sear-D, comprising countries in South East Asia with high adult and high child mortality. DATA SOURCES: Effectiveness data from several sources, including trials, observational studies, and expert opinion. For resource inputs, quantities came from WHO guidelines, literature, and expert opinion, and prices from the WHO choosing interventions that are cost effective database. MAIN OUTCOME MEASURES: Cost per disability adjusted life year (DALY) averted in year 2000 international dollars. RESULTS: The most cost effective mix of interventions was similar in Afr-E and Sear-D. These were the community based newborn care package, followed by antenatal care (tetanus toxoid, screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria and syphilis); skilled attendance at birth, offering first level maternal and neonatal care around childbirth; and emergency obstetric and neonatal care around and after birth. Screening and treatment of maternal syphilis, community based management of neonatal pneumonia, and steroids given during the antenatal period were relatively less cost effective in Sear-D. Scaling up all of the included interventions to 95% coverage would halve neonatal and maternal deaths. CONCLUSION: Preventive interventions at the community level for newborn babies and at the primary care level for mothers and newborn babies are extremely cost effective, but the millennium development goals for maternal and child health will not be achieved without universal access to clinical services as well.",2005-99-01607,16282407,BMJ,Taghreed Adam,2005,331 / 7525,1107,No,16282407,"Taghreed Adam; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries, BMJ, 2005-Nov-12; 331(7525):0959-8138; 1107",DALY,"Bangladesh, Bhutan, India, North Korea, Maldives, Myanmar, Nepal, Timor-Leste",Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Pharmaceutical, Screening","Community Care of newborn + tetanus toxoid + normal delivery by skilled attendant + active management and initial treatment of postpartum haemorrhage+screening for pre-eclampsia and screening for and treatment of asymptomatic bacteriuria+community based management of neonatal pneumonia+neonatal resuscitation+treatment of severe pre-eclampsia or eclampsia+referral of postpartum haemorrhage+management of maternal sepsis+emergency neonatal care+screening and treatment of syphilis+management of obstructed labour, breech presentation, and fetal distress+antibiotics for preterm premature rupture of membranes vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,2808,United States,2000,4220.33
26167,Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries,"OBJECTIVE: To determine the costs and benefits of interventions for maternal and newborn health to assess the appropriateness of current strategies and guide future plans to attain the millennium development goals. DESIGN: Cost effectiveness analysis. SETTING: Two regions classified by the World Health Organization according to their epidemiological grouping: Afr-E, those countries in sub-Saharan Africa with very high adult and high child mortality, and Sear-D, comprising countries in South East Asia with high adult and high child mortality. DATA SOURCES: Effectiveness data from several sources, including trials, observational studies, and expert opinion. For resource inputs, quantities came from WHO guidelines, literature, and expert opinion, and prices from the WHO choosing interventions that are cost effective database. MAIN OUTCOME MEASURES: Cost per disability adjusted life year (DALY) averted in year 2000 international dollars. RESULTS: The most cost effective mix of interventions was similar in Afr-E and Sear-D. These were the community based newborn care package, followed by antenatal care (tetanus toxoid, screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria and syphilis); skilled attendance at birth, offering first level maternal and neonatal care around childbirth; and emergency obstetric and neonatal care around and after birth. Screening and treatment of maternal syphilis, community based management of neonatal pneumonia, and steroids given during the antenatal period were relatively less cost effective in Sear-D. Scaling up all of the included interventions to 95% coverage would halve neonatal and maternal deaths. CONCLUSION: Preventive interventions at the community level for newborn babies and at the primary care level for mothers and newborn babies are extremely cost effective, but the millennium development goals for maternal and child health will not be achieved without universal access to clinical services as well.",2005-99-01607,16282407,BMJ,Taghreed Adam,2005,331 / 7525,1107,No,16282407,"Taghreed Adam; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Stephen S Lim; Sumi Mehta; Zulfiqar A Bhutta; Helga Fogstad; Matthews Mathai; Jelka Zupan; Gary L Darmstadt; Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries, BMJ, 2005-Nov-12; 331(7525):0959-8138; 1107",DALY,"Bangladesh, Bhutan, India, North Korea, Maldives, Myanmar, Nepal, Timor-Leste",Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Pharmaceutical, Screening","Community Care of newborn + tetanus toxoid + normal delivery by skilled attendant + active management and initial treatment of postpartum haemorrhage+screening for pre-eclampsia and screening for and treatment of asymptomatic bacteriuria+community based management of neonatal pneumonia+neonatal resuscitation+treatment of severe pre-eclampsia or eclampsia+referral of postpartum haemorrhage+management of maternal sepsis+emergency neonatal care+screening and treatment of syphilis+management of obstructed labour, breech presentation, and fetal distress+antibiotics for preterm premature rupture of membranes+steroid for preterm birth vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,16930,United States,2000,25445.24
26168,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Algeria, Angola, Benin, Burkina Faso, Cabo Verde, Cameroon, Chad, Comoros, Equatorial Guinea, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Madagascar, Mali, Mauritania, Mauritius, Niger, Nigeria, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Togo",Not Stated,"Environmental, Pharmaceutical",Insecticide treated bed nets (ITNs) vs. Standard/Usual Care,Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,29,United States,2000,43.59
26169,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Algeria, Angola, Benin, Burkina Faso, Cabo Verde, Cameroon, Chad, Comoros, Equatorial Guinea, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Madagascar, Mali, Mauritania, Mauritius, Niger, Nigeria, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Togo",Not Stated,"Environmental, Pharmaceutical",Intermittent presumptive treatment with sulfadoxine-pyrimethamine in pregnancy for malaria vs. Standard/Usual Care,Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,247,United States,2000,371.23
26170,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Algeria, Angola, Benin, Burkina Faso, Cabo Verde, Cameroon, Chad, Comoros, Equatorial Guinea, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Madagascar, Mali, Mauritania, Mauritius, Niger, Nigeria, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Togo",Not Stated,"Environmental, Pharmaceutical",Indoor residual spraying for malaria vs. Standard/Usual Care,Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,32,United States,2000,48.09
26171,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Algeria, Angola, Benin, Burkina Faso, Cabo Verde, Cameroon, Chad, Comoros, Equatorial Guinea, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Madagascar, Mali, Mauritania, Mauritius, Niger, Nigeria, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Togo",Not Stated,"Environmental, Pharmaceutical",Case management with chloroquine for malaria vs. Standard/Usual Care,Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,24,United States,2000,36.07
26172,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Algeria, Angola, Benin, Burkina Faso, Cabo Verde, Cameroon, Chad, Comoros, Equatorial Guinea, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Madagascar, Mali, Mauritania, Mauritius, Niger, Nigeria, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Togo",Not Stated,"Environmental, Pharmaceutical",Case management with sulfadoxine-pyrimethamine for malaria vs. Standard/Usual Care,Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,15,United States,2000,22.54
26173,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Algeria, Angola, Benin, Burkina Faso, Cabo Verde, Cameroon, Chad, Comoros, Equatorial Guinea, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Madagascar, Mali, Mauritania, Mauritius, Niger, Nigeria, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Togo",Not Stated,"Environmental, Pharmaceutical",Case management with non-artemisinin based (CQ-SP) combination treatment (Comb) for malaria vs. Standard/Usual Care,Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,13,United States,2000,19.54
26174,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Algeria, Angola, Benin, Burkina Faso, Cabo Verde, Cameroon, Chad, Comoros, Equatorial Guinea, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Madagascar, Mali, Mauritania, Mauritius, Niger, Nigeria, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Togo",Not Stated,"Environmental, Pharmaceutical",Case management with artemisinin based combination treatment (ACT) for malaria vs. Standard/Usual Care,Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,10,United States,2000,15.03
26175,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Algeria, Angola, Benin, Burkina Faso, Cabo Verde, Cameroon, Chad, Comoros, Equatorial Guinea, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Madagascar, Mali, Mauritania, Mauritius, Niger, Nigeria, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Togo",Not Stated,"Environmental, Pharmaceutical",Insecticide treated bed nets plus case management with chloroquine for malaria vs. Standard/Usual Care,Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,30,United States,2000,45.09
26176,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Algeria, Angola, Benin, Burkina Faso, Cabo Verde, Cameroon, Chad, Comoros, Equatorial Guinea, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Madagascar, Mali, Mauritania, Mauritius, Niger, Nigeria, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Togo",Not Stated,"Environmental, Pharmaceutical",Insecticide treated bed nets plus sulfadoxine-pyrimethamine for malaria vs. Standard/Usual Care,Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,27,United States,2000,40.58
26177,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Algeria, Angola, Benin, Burkina Faso, Cabo Verde, Cameroon, Chad, Comoros, Equatorial Guinea, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Madagascar, Mali, Mauritania, Mauritius, Niger, Nigeria, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Togo",Not Stated,"Environmental, Pharmaceutical","Insecticide treated bed nets, case management with non-artemisinin based (CQ-SP) combination treatment for malaria vs. Standard/Usual Care",Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,26,United States,2000,39.08
26178,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Algeria, Angola, Benin, Burkina Faso, Cabo Verde, Cameroon, Chad, Comoros, Equatorial Guinea, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Madagascar, Mali, Mauritania, Mauritius, Niger, Nigeria, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Togo",Not Stated,"Environmental, Pharmaceutical","Insecticide treated bed nets, case management with artemisinin based combination treatment for malaria vs. Standard/Usual Care",Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,24,United States,2000,36.07
26179,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Algeria, Angola, Benin, Burkina Faso, Cabo Verde, Cameroon, Chad, Comoros, Equatorial Guinea, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Madagascar, Mali, Mauritania, Mauritius, Niger, Nigeria, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Togo",Not Stated,"Environmental, Pharmaceutical",Indoor residual spraying plus case management with chloroquine for malaria vs. Standard/Usual Care,Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,32,United States,2000,48.09
26180,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Algeria, Angola, Benin, Burkina Faso, Cabo Verde, Cameroon, Chad, Comoros, Equatorial Guinea, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Madagascar, Mali, Mauritania, Mauritius, Niger, Nigeria, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Togo",Not Stated,"Environmental, Pharmaceutical",Indoor residual spraying and case management with sulfadoxine-pyrimethamine for malaria vs. Standard/Usual Care,Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,29,United States,2000,43.59
26181,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Algeria, Angola, Benin, Burkina Faso, Cabo Verde, Cameroon, Chad, Comoros, Equatorial Guinea, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Madagascar, Mali, Mauritania, Mauritius, Niger, Nigeria, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Togo",Not Stated,"Environmental, Pharmaceutical",Indoor residual spraying plus case management with non-artemisinin based (CQ-SP) combination treatment for malaria vs. Standard/Usual Care,Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,28,United States,2000,42.08
26182,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Algeria, Angola, Benin, Burkina Faso, Cabo Verde, Cameroon, Chad, Comoros, Equatorial Guinea, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Madagascar, Mali, Mauritania, Mauritius, Niger, Nigeria, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Togo",Not Stated,"Environmental, Pharmaceutical",Indoor residual spraying plus case management with artemisinin based combination treatment for malaria vs. Standard/Usual Care,Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,26,United States,2000,39.08
26183,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Algeria, Angola, Benin, Burkina Faso, Cabo Verde, Cameroon, Chad, Comoros, Equatorial Guinea, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Madagascar, Mali, Mauritania, Mauritius, Niger, Nigeria, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Togo",Not Stated,"Environmental, Pharmaceutical",Indoor residual spraying plus case management with artemisinin based combination treatment plus intermittent presumptive treatment with sulfadoxine-pyrimethamine in pregnancy for malaria vs. Standard/Usual Care,Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,26,United States,2000,39.08
26184,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Algeria, Angola, Benin, Burkina Faso, Cabo Verde, Cameroon, Chad, Comoros, Equatorial Guinea, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Madagascar, Mali, Mauritania, Mauritius, Niger, Nigeria, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Togo",Not Stated,"Environmental, Pharmaceutical",Insecticide treated bed nets plus case management with artemisinin based combination treatment plus intermittent presumptive treatment with sulfadoxine-pyrimethamine in pregnancy for malaria vs. Standard/Usual Care,Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,24,United States,2000,36.07
26185,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Algeria, Angola, Benin, Burkina Faso, Cabo Verde, Cameroon, Chad, Comoros, Equatorial Guinea, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Madagascar, Mali, Mauritania, Mauritius, Niger, Nigeria, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Togo",Not Stated,"Environmental, Pharmaceutical",Insecticide treated bed nets plus indoor residual spraying for malaria vs. Standard/Usual Care,Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,35,United States,2000,52.6
26186,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Botswana, Burundi, Central African Republic, Congo Democratic Republic, Congo, Cte d'Ivoire, Eritrea, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe",Not Stated,"Environmental, Pharmaceutical",Insecticide treated bed nets plus indoor residual spraying plus case management with artemisinin based combination treatment for malaria vs. Standard/Usual Care,Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,32,United States,2000,48.09
26187,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Botswana, Burundi, Central African Republic, Congo Democratic Republic, Congo, Cte d'Ivoire, Eritrea, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe",Not Stated,"Environmental, Pharmaceutical",Insecticide treated bed nets (ITNs) vs. Standard/Usual Care,Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,41,United States,2000,61.62
26188,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Botswana, Burundi, Central African Republic, Congo Democratic Republic, Congo, Cte d'Ivoire, Eritrea, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe",Not Stated,"Environmental, Pharmaceutical",Intermittent presumptive treatment with sulfadoxine-pyrimethamine in pregnancy for malaria vs. Standard/Usual Care,Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,352,United States,2000,529.04
26189,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Botswana, Burundi, Central African Republic, Congo Democratic Republic, Congo, Cte d'Ivoire, Eritrea, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe",Not Stated,"Environmental, Pharmaceutical",Indoor residual spraying for malaria vs. Standard/Usual Care,Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,41,United States,2000,61.62
26190,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Botswana, Burundi, Central African Republic, Congo Democratic Republic, Congo, Cte d'Ivoire, Eritrea, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe",Not Stated,"Environmental, Pharmaceutical",Case management with chloroquine for malaria vs. Standard/Usual Care,Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,29,United States,2000,43.59
26191,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Botswana, Burundi, Central African Republic, Congo Democratic Republic, Congo, Cte d'Ivoire, Eritrea, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe",Not Stated,"Environmental, Pharmaceutical",Case management with sulfadoxine-pyrimethamine for malaria vs. Standard/Usual Care,Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,17,United States,2000,25.55
26192,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Botswana, Burundi, Central African Republic, Congo Democratic Republic, Congo, Cte d'Ivoire, Eritrea, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe",Not Stated,"Environmental, Pharmaceutical",Case management with non-artemisinin based (CQ-SP) combination treatment (Comb) for malaria vs. Standard/Usual Care,Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,16,United States,2000,24.05
26193,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Botswana, Burundi, Central African Republic, Congo Democratic Republic, Congo, Cte d'Ivoire, Eritrea, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe",Not Stated,"Environmental, Pharmaceutical",Case management with artemisinin based combination treatment (ACT) for malaria vs. Standard/Usual Care,Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,12,United States,2000,18.04
26194,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Botswana, Burundi, Central African Republic, Congo Democratic Republic, Congo, Cte d'Ivoire, Eritrea, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe",Not Stated,"Environmental, Pharmaceutical",Insecticide treated bed nets plus case management with chloroquine for malaria vs. Standard/Usual Care,Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,39,United States,2000,58.62
26195,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Botswana, Burundi, Central African Republic, Congo Democratic Republic, Congo, Cte d'Ivoire, Eritrea, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe",Not Stated,"Environmental, Pharmaceutical",Insecticide treated bed nets plus sulfadoxine-pyrimethamine for malaria vs. Standard/Usual Care,Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,31,United States,2000,46.59
26196,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Botswana, Burundi, Central African Republic, Congo Democratic Republic, Congo, Cte d'Ivoire, Eritrea, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe",Not Stated,"Environmental, Pharmaceutical","Insecticide treated bed nets, case management with non-artemisinin based (CQ-SP) combination treatment for malaria vs. Standard/Usual Care",Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,34,United States,2000,51.1
26197,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Botswana, Burundi, Central African Republic, Congo Democratic Republic, Congo, Cte d'Ivoire, Eritrea, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe",Not Stated,"Environmental, Pharmaceutical","Insecticide treated bed nets, case management with artemisinin based combination treatment for malaria vs. Standard/Usual Care",Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,28,United States,2000,42.08
26198,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Botswana, Burundi, Central African Republic, Congo Democratic Republic, Congo, Cte d'Ivoire, Eritrea, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe",Not Stated,"Environmental, Pharmaceutical",Indoor residual spraying plus case management with chloroquine for malaria vs. Standard/Usual Care,Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,40,United States,2000,60.12
26199,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Botswana, Burundi, Central African Republic, Congo Democratic Republic, Congo, Cte d'Ivoire, Eritrea, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe",Not Stated,"Environmental, Pharmaceutical",Indoor residual spraying and case management with sulfadoxine-pyrimethamine for malaria vs. Standard/Usual Care,Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,36,United States,2000,54.11
26200,Cost effectiveness analysis of strategies to combat malaria in developing countries,"OBJECTIVE: To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. DESIGN: Generalised cost effectiveness analysis. DATA SOURCES: Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. METHODS: Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. RESULTS: High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. CONCLUSIONS: A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.",2005-99-01608,16282381,BMJ,Chantal M Morel,2005,331 / 7528,1299,No,16282381,"Chantal M Morel; Jeremy A Lauer; David B Evans; Jeremy A Lauer; David B Evans; Cost effectiveness analysis of strategies to combat malaria in developing countries, BMJ, 2005-Dec-03; 331(7528):0959-8138; 1299",DALY,"Botswana, Burundi, Central African Republic, Congo Democratic Republic, Congo, Cte d'Ivoire, Eritrea, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe",Not Stated,"Environmental, Pharmaceutical",Indoor residual spraying plus case management with non-artemisinin based combination treatment for malaria vs. Standard/Usual Care,Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,35,United States,2000,52.6
